

**Manuscript version: Author's Accepted Manuscript**

The version presented in WRAP is the author's accepted manuscript and may differ from the published version or Version of Record.

**Persistent WRAP URL:**

<http://wrap.warwick.ac.uk/128560>

**How to cite:**

Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

**Copyright and reuse:**

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

**Publisher's statement:**

Please refer to the repository item page, publisher's statement section, for further information.

For more information, please contact the WRAP Team at: [wrap@warwick.ac.uk](mailto:wrap@warwick.ac.uk).

1 **NCAM Regulates Temporal Specification of Neural Progenitor Cells via Profilin2**  
2 **during Corticogenesis**

3 Rui Huang<sup>1#</sup>, De-Juan Yuan<sup>2, 3#</sup>, Shao Li<sup>3#</sup>, Xue-Song Liang<sup>1</sup>, Yue Gao<sup>1</sup>, Xiao-Yan Lan<sup>1</sup>, Hua-  
4 Min Qin<sup>4</sup>, Yu-Fang Ma<sup>5</sup>, Guang-Yin Xu<sup>2</sup>, Melitta Schachner<sup>6, 7</sup>, Vladimir Sytnyk<sup>8</sup>, Johannes  
5 Boltze<sup>9</sup>, Quan-Hong Ma<sup>2\*</sup>, Shen Li<sup>1\*</sup>

6  
7 <sup>1</sup>Neurology Department, Dalian Municipal Central Hospital affiliated to Dalian Medical  
8 University, Dalian, China

9 <sup>2</sup>Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases,  
10 Institute of Neuroscience, Soochow University, Suzhou, China

11 <sup>3</sup>Physiology Department, Dalian Medical University, Dalian, China

12 <sup>4</sup>Pathology Department, the Second Hospital of Dalian Medical University, Dalian, China

13 <sup>5</sup>Biochemistry and Molecular Biology Department, Dalian Medical University, Dalian, China

14 <sup>6</sup>Center for Neuroscience, Shantou University Medical College, Shantou, China

15 <sup>7</sup>Keck Center for Collaborative Neuroscience and Department of Cell Biology and  
16 Neuroscience, Rutgers University, New Jersey, USA

17 <sup>8</sup>School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney,  
18 Australia

19 <sup>9</sup>School of Life Sciences, University of Warwick, Coventry, United Kingdom

20 <sup>#</sup>Equal contribution

21  
22 <sup>\*</sup>Correspondence to Shen Li: listenlishen@hotmail.com; Department of Neurology, Dalian  
23 Municipal Central Hospital affiliated to Dalian Medical University, No. 826 Xinan Road,  
24 Dalian 116033, China; ORCID ID: <https://orcid.org/0000-0001-6779-9812>; or Quanhong Ma:  
25 maquanhong@suda.edu.cn; Block 402, No. 199 Ren-Ai Road, Suzhou 215021, China.

26 **Running title:** NCAM regulates temporal NPC specification

27

## 28 **Summary**

29 The role of NCAM in corticogenesis is incompletely understood. The authors demonstrate  
30 that NCAM controls NPC proliferation and fate decision through profilin2-dependent  
31 regulation of actin polymerization. This finding sheds new light on NCAM's functions in  
32 neurodevelopmental and mental disorders.

33

## 34 **Abstract**

35 The development of cerebral cortex requires spatially and temporally orchestrated  
36 proliferation, migration and differentiation of neural progenitor cells (NPCs). The molecular  
37 mechanisms underlying cortical development are, however, not fully understood. The neural  
38 cell adhesion molecule (NCAM) has been suggested to play a role in corticogenesis. Here we  
39 show that NCAM is dynamically expressed in the developing cortex. NCAM expression in  
40 NPCs is highest in the neurogenic period and declines during the gliogenic period. In mice  
41 bearing an NPC-specific NCAM deletion, proliferation of NPCs is reduced, and production of  
42 cortical neurons is delayed, while formation of cortical glia is advanced. Mechanistically,  
43 NCAM enhances actin polymerization in NPCs by interacting with actin-associated protein  
44 profilin2. NCAM-dependent regulation of NPCs is blocked by mutations in the profilin2  
45 binding site. Thus, NCAM plays an essential role in NPC proliferation and fate decision during  
46 cortical development by regulating profilin2-dependent actin polymerization.

47

48 **Keywords:** NCAM, profilin2, cerebral cortex, neural progenitor cell, actin

## 49 **Introduction**

50 The development of the mammalian cerebral cortex requires spatially and temporally  
51 orchestrated proliferation, migration, and differentiation of neural progenitor cells (NPCs)  
52 (Greig et al., 2013). Radial glial cells (RGCs) in the ventricular zone (VZ) contribute to the  
53 generation of cortical layers directly or indirectly through intermediate progenitor cells (IPCs)  
54 (Gal et al., 2006; Haubensak et al., 2004). Cortical neurons are generated in a defined temporal  
55 sequence, in which neurons in deeper layers are generated first. Following neurogenesis,  
56 astrocytes appear shortly before birth, whereas oligodendrocytes emerge postnatally in  
57 mammals (Kohwi and Doe, 2013). Both intrinsic and extrinsic factors contribute to this  
58 developmental sequence. In humans, disturbance of this highly elaborate process leads to  
59 neurodevelopmental defects ranging between devastating malformations and relatively mild  
60 abnormalities causing neurological diseases such as epilepsy, schizophrenia and autism  
61 spectrum disorders (Gaspard and Vanderhaeghen, 2011).

62 The neural cell adhesion molecule (NCAM) is a membrane-bound cell recognition  
63 molecule of the immunoglobulin superfamily. NCAM contributes to the nervous system  
64 development by influencing neuronal migration, neurite outgrowth, synapse formation, and  
65 synaptic plasticity (Sytnyk et al., 2017). Alternative splicing of NCAM transcripts generates  
66 three major isoforms: NCAM180, -140, and -120. NCAM180 and NCAM140 are  
67 transmembrane isoforms bearing an intracellular domain, which is longer in NCAM180.  
68 NCAM120 is anchored to the membrane via a glycosylphosphatidylinositol linkage (Sytnyk et  
69 al., 2017). Soluble extracellular NCAM fragments can be produced by NCAM ectodomain  
70 shedding (Hubschmann et al., 2005; Secher, 2010). NCAM knockout mice display an abnormal  
71 brain structure as well as learning and behavioral abnormalities (Brandewiede et al., 2014;  
72 Bukalo et al., 2004; Stork et al., 1999; Wood et al., 1998). Moreover, single nucleotide  
73 polymorphisms in the *NCAM* gene and/or abnormal polysialylation or proteolysis of NCAM

74 protein alter NCAM function in neurodevelopmental, neuropsychiatric, and neurodegenerative  
75 disorders in humans (Brenneman and Maness, 2010; Hidese et al., 2017; Purcell et al., 2001;  
76 Wang et al., 2012), suggesting a crucial role of NCAM in cortical development.

77 NCAM plays a role in regulation of neurogenesis. Recombinant soluble NCAM reduces  
78 hippocampal NPC proliferation by heterophilic binding to an unknown cell surface receptor  
79 (Amoureux et al., 2000; Shin et al., 2002). Soluble NCAM and overexpression of NCAM140  
80 in NPCs promote differentiation of NPCs into the neuronal lineage (Amoureux et al., 2000;  
81 Kim and Son, 2006; Kim et al., 2005; Klein et al., 2014), while ectopic expression of  
82 NCAM140 in RGCs increases cell proliferation *in vivo* (Boutin et al., 2009). However, it is  
83 unknown whether NCAM is an intrinsic modulator of NPC proliferation and differentiation.

84 Regulation of the cell cycle plays a crucial role in controlling temporal and spatial  
85 production of neural cells (Dehay and Kennedy, 2007; Politis et al., 2008). Cell cycle  
86 progression is modulated by the actin cytoskeleton which regulates cell rounding and rigidity  
87 for proper positioning and spindle orientation during mitosis (Heng and Koh, 2010; Kunda and  
88 Baum, 2009). Actin cytoskeleton reorganization during mitosis is controlled by actin-binding  
89 proteins, among which profilins are essential for cytokinesis (Suetsugu et al., 1999). Profilins  
90 are a conserved family of small proteins that facilitate the addition of actin monomers to the  
91 fast growing end of actin filaments by accelerating the ADP-ATP nucleotide exchange (Witke,  
92 2004). Among the four profilin subtypes, profilin2 is most expressed in the central nervous  
93 system (Di Nardo et al., 2000) where it contributes to maintaining spine density and dendritic  
94 complexity (Michaelsen et al., 2010). Profilin2 also stabilizes spine structure, controls  
95 presynaptic vesicular exocytosis (Pilo-Boyl et al., 2007), and is required for synaptic plasticity  
96 (Chakraborty et al., 2014). However, the role of profilins in cortical development is so far  
97 unknown.

## 98 **Results**

### 99 **NCAM is dynamically expressed in NPCs during cortical development**

100 We first examined the NCAM expression profile. NCAM levels, particularly of the  
101 NCAM180 and NCAM140 isoforms, steadily increased in the developing mouse cortex (**Fig.**  
102 **S1A-F**). To further analyze the expression of NCAM in distinct cell types, coronal cortical  
103 sections at different embryonic stages (embryonic day 12 (E12) to postnatal day 0 (P0)) were  
104 co-immunostained for NCAM and either Sox2 (NPCs) or Tuj1 (neurons), respectively. NCAM  
105 was expressed in both NPCs (**Fig. 1A**) and neurons (**Fig. 1B**) in the developing cortex.  
106 Quantification of NCAM immunofluorescence intensities revealed that NCAM was  
107 predominantly expressed by NPCs in the ventricular zone/subventricular zone (VZ/SVZ), and  
108 by neurons in the intermediate zone (IZ), cortical plate (CP), and marginal zone (MZ) during  
109 the early neurogenic period (E12 to E14). Interestingly, NCAM immunofluorescence intensity  
110 in VZ/SVZ in relation to that in the total dorsal brain (**Fig. 1C**) as well as average NCAM  
111 immunofluorescence density in VZ/SVZ (**Fig. 1D**) decreased from E16 onward reaching the  
112 lowest level at E18 and P0 (gliogenic period). In contrast, NCAM immunoreactivity did not  
113 change in the IZ and MZ and even increased in the CP at E18 and P0 compared to E16,  
114 indicating that NCAM levels are maintained during these developmental stages in areas  
115 enriched in cortical neurons. (**Fig. 1A-D** and **Fig. S1H**). These results indicate that NCAM is  
116 expressed in NPCs in the early neurogenic period, whereas NCAM expression in NPCs declines  
117 during the gliogenic period.

118

### 119 **NCAM deficiency results in transiently reduced NPC proliferation in the developing** 120 **cerebral cortex**

121 We next examined the role of NCAM in NPCs by generating NCAM conditional knockout  
122 (cKO) mice via crossing NCAM-floxed mice with Nestin-cre mice to ablate NCAM expression

123 in NPCs. NCAM was not detectable in NPCs (**Fig. S1H**) and other brain cell populations (data  
124 not shown) in NCAM cKO mice. We then examined whether NPC pool was affected by NCAM  
125 deficiency. Numbers of Pax6<sup>+</sup> RGCs were reduced in the VZ in NCAM cKO mice at E12 and  
126 E14, but not at E16 and E18 compared to control littermates (**Fig. 2A, B**). Numbers of Tbr2<sup>+</sup>  
127 IPCs, which mainly localize in SVZ, were also decreased in NCAM cKO mice at E12, but not  
128 at E14 and E16 (**Fig. 2E, F**). These results indicate that NCAM deficiency leads to transient  
129 reduction of NPC numbers during cortical development.

130 The total number of BrdU<sup>+</sup> cells (**Fig. 2C**) and the percentage of proliferating  
131 Pax6<sup>+</sup>BrdU<sup>+</sup>/Pax6<sup>+</sup> RGCs (**Fig. 2D**) were reduced in NCAM cKO mice compared to control  
132 littermates at E12 and E14, but not at E16 and E18, indicating that NCAM regulates RGC  
133 proliferation only during earlier developmental stages. Consistently, the numbers of Ki67<sup>+</sup> (**Fig.**  
134 **2G, H**) or PH3<sup>+</sup> (**Fig. 2I, J**) cells, representing cells in the cell cycle or in mitosis, were also  
135 decreased in E12 NCAM cKO mice. This finding suggests that NCAM deficiency results in  
136 fewer NPCs in the cell cycle and mitosis at this stage. The decreased proliferation of NCAM  
137 cKO NPCs was not due to enhanced apoptosis, as the numbers of cleaved active caspase3<sup>+</sup>  
138 NPCs were similar in NCAM cKO and control littermates at E12, E14, and E16 (**Fig. S2**).

139 We also analyzed whether NCAM deficiency affects cell cycle exit and length in the  
140 VZ/SVZ. The cell cycle exit index (proportion of BrdU<sup>+</sup>Ki67<sup>-</sup> cells in BrdU<sup>+</sup> cell population)  
141 was increased at E14 in the VZ/SVZ of NCAM cKO mice compared to control littermates (**Fig.**  
142 **2K, L**). S-phase length, estimated by the proportion of BrdU<sup>+</sup>Ki67<sup>+</sup> cells in the Ki67<sup>+</sup> cell  
143 population, was not altered at E14 (**Fig. 2K, M**). These data indicate that NCAM deficiency  
144 results in enhanced cell cycle exit and decreased NPC proliferation, eventually reducing the  
145 NPC pool during early neurogenic period.

146

147 **NCAM deficiency delays the generation of cortical neurons**

148 Next, we analyzed whether NCAM regulates the generation of layer-specific neurons at  
149 different embryonic stages. The numbers of Tbr1<sup>+</sup> neurons in layer VI in NCAM cKO cortices  
150 were decreased at E12 and E14, increased at E16, and unaltered at E18 (**Fig. 3A, D**). Ctip2<sup>+</sup>  
151 neuron numbers in layer V in NCAM cKO mice were decreased at E12 and E14, but unchanged  
152 at E16 (**Fig. 3B, E**). The numbers of Cux1<sup>+</sup> neurons in layers II–IV in NCAM cKO mice were  
153 reduced at E16, E18 and P0, but returned to control levels at P7 (**Fig. 3C, F**). Spatial distribution  
154 of these cortical neurons was unaltered in NCAM cKO mice (**Fig. S3**), suggesting that the lower  
155 numbers of cortical neurons observed in NCAM cKO mice are not caused by a migration defect.

156 Decreased numbers of both deep- and upper-layer cortical neurons at earlier developmental  
157 stages, but normal levels at later developmental stages can also be explained by a delayed  
158 generation of cortical neurons in NCAM deficient mice. To assess this possibility, we performed  
159 birth-dating analysis to examine the generation date of distinct cortical neurons. Pregnant mice  
160 were injected with BrdU at E11.5, E14.5, E15.5, or E16.5. The embryos were collected at either  
161 E18 (for analysis of Tbr1<sup>+</sup> and Ctip2<sup>+</sup> neuron generation) or P2 (for analysis of Cux1<sup>+</sup> neuron  
162 generation). The proportion of cell-specific neurons born at the time of injection (BrdU<sup>+</sup>marker<sup>+</sup>  
163 cells/total number of marker<sup>+</sup> cells) was analyzed. Generation of Tbr1<sup>+</sup> and Ctip2<sup>+</sup> neurons was  
164 lower at E11.5 (**Fig. 4A, B, D**), but higher at E14.5 (**Fig. 4A, B, E**) in NCAM cKO mice. This  
165 inter-genotype difference diminished at E15.5 (**Fig. 4A, B, F**) when deep-layer neuron  
166 generation is close to completion. These data aligned well with our findings that the numbers  
167 of deep-layer neurons were reduced in NCAM cKO mice at E12 and E14, but were normal by  
168 E18 (**Fig. 3D, E**). The generation of upper-layer neurons (Cux1<sup>+</sup>BrdU<sup>+</sup>/Cux1<sup>+</sup>cells) was  
169 reduced at E16.5 in NCAM cKO mice (**Fig. 4C, G**), which could explain the decreased numbers  
170 of upper-layer neurons from E16 to P0 (**Fig. 3F**). The number of upper-layer neurons in NCAM  
171 cKO mice was normal at P7 (**Fig. 3F**), indicating a postnatal “rescue” generation of upper-layer

172 neurons. In summary, these data strongly indicate that NCAM regulates the temporal generation  
173 of cortical neurons.

174

### 175 **NCAM deficiency leads to precocious gliogenesis**

176 We further examined whether NCAM regulates the temporal generation of glial cells. More  
177 GFAP<sup>+</sup> cells were observed in NCAM cKO mice than in control littermates at E18 and P0 (**Fig.**  
178 **5A, B**). Interestingly, GFAP<sup>+</sup> cells were observed in the VZ/SVZ of NCAM cKO mice at E16  
179 (**Fig. 5A, C**) while fewer GFAP<sup>+</sup> cells were observed in control brains at this stage because  
180 astrocytes normally do not appear before E18 (Miller and Gauthier, 2007; Molofsky et al.,  
181 2012). The result indicates an earlier appearance of astrocytes in NCAM cKO mice. The inter-  
182 genotype difference diminished at P7, when astrocyte generation is close to completion (Wang  
183 and Bordey, 2008) (**Fig. 5A, B**). Birth-dating analysis of astrocytes by BrdU pulse-labeling at  
184 the onset of their generation at E16.5 (Miller and Gauthier, 2007) and calculating the numbers  
185 of BrdU<sup>+</sup>GFAP<sup>+</sup> cells at P2 revealed more BrdU<sup>+</sup>GFAP<sup>+</sup> cells in NCAM cKO mice (**Fig. 5D,**  
186 **E**), indicating an increased generation of astrocytes at E16.5 in NCAM cKO mice. Numbers of  
187 Olig2<sup>+</sup> oligodendrocytes were increased in NCAM cKO brains at E18, but similar to those in  
188 control mice at P0 (**Fig. 5F, G**). Birth-dating analysis of oligodendrocytes by BrdU pulse-  
189 labeling at E16.5 showed that the percentage of BrdU<sup>+</sup>Olig2<sup>+</sup> cells was increased in NCAM  
190 cKO mice at P2 (**Fig. 5H, I**). Consistent with these results, numbers of cells expressing brain  
191 lipid binding protein (BLBP) (**Fig. 5L, M**), which is initially expressed in RGCs and later  
192 becomes restricted to astrocytes (Feng et al., 1994; Kurtz et al., 1994), as well as numbers of  
193 cells expressing A2B5, a marker of immature glial restricted progenitors (BaracsKay et al.,  
194 2007; Dietrich et al., 2002) (**Fig. 5J, K**), were increased in the brains of NCAM cKO mice at  
195 E14 and E16, respectively. This increase was not due to an expansion of the RGC pool since  
196 the numbers of Pax6<sup>+</sup> RGCs were reduced at E14 and reached normal levels at E16 (**Fig. 2A,**

197 **B).** Thus, the increase in numbers of BLBP<sup>+</sup> and A2B5<sup>+</sup> cells is likely due to an enhanced glial  
198 progenitor density, reflecting an earlier glial specification. Taken together, these results suggest  
199 that NCAM deficiency in NPCs results in precocious gliogenesis.

200

## 201 **Profilin2 binds to NCAM**

202 To investigate the molecular mechanisms underlying NCAM-dependent cortical  
203 development, yeast two-hybrid screening was performed with NCAM140 as a bait (Li et al.,  
204 2013). NCAM140 in NPCs is expressed at higher levels relative to other isoforms  
205 (Prodromidou et al., 2014). Among >2x10<sup>6</sup> clones screened, 26 clones were positive. A BLAST  
206 database search (<http://www.ncbi.nlm.nih.gov/BLAST/>) indicated that one clone, encoding full  
207 length profilin2, was in the correct open reading frame. To confirm the association between  
208 NCAM and profilin2, NCAM was immunoprecipitated from neonatal brain homogenates using  
209 polyclonal antibodies recognizing NCAM extracellular domain. Western blot analysis showed  
210 that profilin2 was co-immunoprecipitated by NCAM antibodies. Inversely, NCAM120,  
211 NCAM140, NCAM180, and soluble NCAM105 were co-immunoprecipitated by profilin2  
212 antibodies (**Fig. 6A**). Direct binding was assessed by ELISA, with profilin2 being substrate-  
213 coated and probed by the recombinantly expressed intracellular domains of NCAM140 and  
214 NCAM180. NCAM140, but notably not NCAM180, bound to profilin2 in a concentration-  
215 dependent and saturable manner (**Fig. 6B**). Identification of profilin2-binding sites in NCAM  
216 revealed that peptides encoding aa729-750 and aa748-763 bound to profilin2 (**Fig. 6C**). These  
217 two peptides had three overlapping amino acids: asparagine (N<sup>748</sup>), leucine (L<sup>749</sup>), and cysteine  
218 (C<sup>750</sup>). To investigate whether these amino acids mediated the binding to profilin2, binding of  
219 profilin2 to a non-mutated <sup>745</sup>IAVNLCGKA<sup>753</sup> peptide comprising the NLC motif and two  
220 mutated peptides (with two of these three amino acids changed at a time) was analyzed.  
221 Mutation of L<sup>749</sup> and C<sup>750</sup> into alanine (A<sup>749</sup>) and serine (S<sup>750</sup>) completely blocked the binding

222 to profilin2 (**Fig. 6D**). Mutation of N<sup>748</sup> and L<sup>749</sup> into glutamine (Q<sup>748</sup>) and alanine (A<sup>749</sup>)  
223 partially suppressed the interaction, suggesting that N<sup>748</sup> is not crucial for it (**Fig. 6D**). Mutation  
224 of <sup>749</sup>LC<sup>750</sup> in the recombinant intracellular domain of NCAM140 to <sup>749</sup>AS<sup>750</sup> also abolished its  
225 binding to profilin2 as tested by ELISA, confirming that L<sup>749</sup> and C<sup>750</sup> are essential for the  
226 binding of NCAM140 to profilin2 (**Fig. 6E, F**).

227

### 228 **Profilin2 exhibits an expression pattern similar to that of NCAM in the developing cortex**

229 To analyze whether NCAM co-localizes with profilin2 in the developing cortex, cortical  
230 sections of E12-P0 wild type mice were co-immunostained for NCAM, profilin2, and Sox2  
231 (**Fig. 6G**), or Tuj1 (**Fig. 6H**). Profilin2 co-localized with NCAM at all developmental stages  
232 analyzed exhibiting an expression pattern similar to that of NCAM (**Fig. 6I, J, S5B**). Although  
233 profilin2 levels increased in the whole brain during development (**Fig. S1A, G**), both the  
234 average profilin2 immunofluorescence density in VZ/SVZ (**Fig. 6I**) as well as the percentage  
235 of profilin2 immunofluorescence intensity in VZ/SVZ to that in the total dorsal brain (**Fig. 6J**)  
236 decreased. This was particularly evident in the gliogenic period. Profilin2 protein (**Fig. 6K, L**)  
237 and mRNA (**Fig. 6M**) expression were reduced in NCAM cKO versus wild type NPCs,  
238 suggesting that NCAM regulates profilin2 expression and further implying the functional  
239 relationship between these two proteins.

240

### 241 **Profilin2 is required for NCAM-dependent NPC proliferation and differentiation**

242 To explore whether NCAM controls the proliferation of NPCs through profilin2, BrdU  
243 incorporation was analyzed in cultured NPCs transfected with either profilin2 siRNA  
244 (siProfilin2) or control (scrambled) siRNA (NC). NPCs were analyzed after incubation with or  
245 without NCAM antibodies recognizing NCAM extracellular domain and triggering  
246 downstream signaling of NCAM (Li et al., 2013). Transfection of siProfilin2 suppressed

247 profilin2 (**Fig. S4A, B, C**), but not profilin1 expression (**Fig. S4D**) in Neuro-2a cells and NPCs,  
248 and decreased NPC proliferation (**Fig. 7A, C**; siprofilin2-399). Incubation with NCAM  
249 antibodies increased proliferation of NPCs transfected with control siRNA, but not of NPCs  
250 transfected with siProfilin2 (**Fig. 7A, C**). This indicates that NCAM promotes the proliferation  
251 of NPCs through profilin2.

252 To investigate whether profilin2 plays a role in NCAM-dependent differentiation of NPCs,  
253 NC- or siProfilin2 (siProfilin2-399)-transfected NPCs were allowed to differentiate in the  
254 absence or presence of NCAM antibodies for 5 days. Immunofluorescence analysis showed  
255 that the percentages of Tuj1<sup>+</sup> cells (**Fig. 7B, D**) were decreased, whereas the percentages of  
256 GFAP<sup>+</sup> (**Fig. 7E, G**) and O4<sup>+</sup> cells (**Fig. 7F, H**) were increased by profilin2 knockdown. These  
257 observations indicate that profilin2, similar to NCAM, promotes neuronal differentiation and  
258 suppresses differentiation of NPCs into glial cells. Consistent with *in-vivo* results, NCAM  
259 antibody treatment increased the percentages of Tuj1<sup>+</sup> cells (**Fig. 7B, D**) but decreased GFAP<sup>+</sup>  
260 (**Fig. 7E, G**) and O4<sup>+</sup> cell percentages (**Fig. 7F, H**) in NC-transfected NPCs. However, the effect  
261 of NCAM antibodies on neuronal and astroglial differentiation was abolished in NPCs  
262 transfected with siProfilin2 (**Fig. 7B, D, E, G**), indicating that profilin2 is required for NCAM-  
263 dependent regulation of neuronal and astroglial differentiation. Profilin2 knockdown reduced,  
264 but did not abolish the suppressing effect of NCAM antibodies on oligodendroglial  
265 differentiation (**Fig. 7F, H**). To further confirm that profilin2 is involved in NCAM-regulated  
266 NPC differentiation in a cell autonomous manner, NPCs were transfected with shRNA Profilin2  
267 (shProfilin2) alone or together with shRNA-resistant profilin2 plasmids encoding GFP under a  
268 separate promoter. NPCs were then treated with NCAM antibodies. NCAM antibody-enhanced  
269 neurogenesis and -decreased astrogenesis were prevented by profilin2 knockdown, which was  
270 rescued by cotransfection with shRNA-resistant profilin2 (**Fig. 7I-K**). Therefore, these results  
271 indicate that profilin2 is the downstream effector of NCAM, through which NCAM regulates

272 NPC proliferation and differentiation.

273

## 274 **NCAM regulates actin cytoskeleton dynamics through profilin2**

275 We further tested whether NCAM regulates NPC proliferation and differentiation through  
276 profilin2-mediated actin polymerization. Western blot analysis of total cell lysates showed that  
277 the expression of actin did not differ between control and NCAM cKO NPCs. However, the  
278 depolymerized actin (G-actin) levels were higher in NCAM cKO NPCs. Proportionally, the  
279 polymerized actin (F-actin) levels were reduced in NCAM cKO NPCs (**Fig. 8A, B**), indicating  
280 that NCAM promotes actin polymerization. Western blot analysis revealed that NCAM  
281 knockdown-induced reduction of the F-/G-actin ratio was rescued by wild type NCAM140, but  
282 not mutNCAM (unable to bind profilin2) in mouse embryonic fibroblasts (**Fig. 8C**). To confirm  
283 these data, control and NCAM cKO NPCs expressing GFP only, co-expressing wild type  
284 NCAM140, or mutNCAM were stained by fluorescent phalloidin and deoxyribonuclease I to  
285 visualize F- and G-actin, respectively. Fluorescent microscopy analysis showed that the F-/G-  
286 actin ratio was reduced in NCAM cKO NPCs. Lentiviral transduction with wild type  
287 NCAM140, but not mutNCAM, increased the F-/G-actin ratio in NCAM cKO NPCs to control  
288 levels (**Fig. 8D, E**). The decreased F-/G-actin ratio in NCAM cKO NPCs was also rescued by  
289 profilin2 overexpression (**Fig. 8F, G**). These results indicate that NCAM promotes actin  
290 polymerization through its binding to profilin2.

291 Actin cytoskeleton is crucial for soma rounding, and for increased rigidity during cell  
292 division (Kunda and Baum, 2009). The role of NCAM in cell shape alteration was investigated  
293 in dividing cells, and the cell shape index (CSI) of NPCs was calculated in meta- and anaphase  
294 at the VZ surface. NCAM deficiency leads to elongated morphology of NPCs and reduced CSI  
295 values (**Fig. 8H, I**), indicating that mitotic NPCs in NCAM cKO mice fail to round up, what is  
296 believed to lead to the perturbation of cell cycle progression (Heng and Koh, 2010).

297        Immunofluorescence analysis showed reduced NPC proliferation and neurogenesis, and  
298 increased astrogenesis in NCAM cKO NPCs (**Fig. 8J-N**). Transduction of NCAM cKO NPCs  
299 with wild type NCAM140, but not mutNCAM-expressing lentiviruses, normalized  
300 proliferation, neurogenesis and astrogenesis (**Fig. 8J-N**). Hence, NCAM controls the  
301 proliferation and differentiation of NPCs through binding to profilin2 via regulation of actin  
302 cytoskeleton dynamics.

303 **Discussion**

304 We demonstrated that NCAM is dynamically expressed in the developing cortex with high  
305 expression in NPCs during the neurogenic period and lower expression in NPCs in the gliogenic  
306 period. Expression of NCAM is required for maintenance of the precise proliferation and the  
307 timely generation of cortical neurons and glial cells. Furthermore, profilin2 was identified to be  
308 the mediator of NCAM-dependent regulation of cytoskeleton dynamics controlling NPC  
309 proliferation and differentiation during cortical development (**Fig. 9**).

310 Previous studies suggested that NCAM can function as both a cell-extrinsic and cell-  
311 intrinsic signaling molecule in NPCs (Amoureux et al., 2000; Boutin et al., 2009; Kim and Son,  
312 2006; Klein et al., 2014; Prodromidou et al., 2014). The present study confirms these views by  
313 showing that specific ablation of NCAM expression in NPCs suppressed proliferation and  
314 enhanced cell cycle exit of NPCs at the earlier neurogenic stage, leading to a transiently reduced  
315 NPC pool. At later developmental stages, i.e. from E16 onwards, neither proliferation of NPCs  
316 nor NPC numbers in NCAM mutant mice were different from that in wild type mice.  
317 Interestingly, NCAM expression in NPCs was reduced from E16 onward, showing considerably  
318 reduced levels at the gliogenic period. Thus, the loss of NCAM-dependent regulation of NPC  
319 proliferation at later developmental stages may be due to the decline in NCAM expression.  
320 However, the fact that the transiently decreased proliferation in the earlier neurogenic period  
321 does not lead to an ultimately depleted NPC pool at later developmental stages also suggests a  
322 compensatory mechanism.

323 During brain development, a number of cell cycle regulators are involved in cell fate  
324 specification while key factors for cell fate specification influence cell cycle (Politis et al.,  
325 2008). In line with this notion, we observed a delayed generation of both upper- and deep-layer  
326 cortical neurons and a precocious gliogenesis in NCAM mutant mice. Furthermore, the  
327 transiently increased cell cycle exit upon NCAM deletion is paralleled by increased numbers

328 of glial progenitors during the neurogenic period, suggesting that cells exiting the cell cycle at  
329 E14 may adopt a glial fate. Consistently, GFAP<sup>+</sup> astrocytes were observed in NCAM cKO  
330 brains as early as E16, despite the fact that astrocytes normally do not appear in rodent brains  
331 until E18 (Miller and Gauthier, 2007). Hence, it is likely that precocious astrogenesis is due to  
332 depletion of NCAM in NPCs at early rather than later development stages when NCAM  
333 expression in NPCs decreases. Gliogenesis is suppressed during the neurogenic period, and  
334 induced after neurons had been generated in sufficient numbers (Sloan and Barres, 2014).  
335 However, NCAM cKO mice exhibit a delayed neurogenesis. Thus, it is unlikely that the  
336 precocious astrogliogenesis observed in NCAM cKO mice is due to the delayed generation of  
337 neurons. Moreover, transfection of plasmids encoding NCAM decreased astrogliogenesis from  
338 cultured NCAM cKO NPCs, further confirming a cell-autonomous mechanism. Thus, we  
339 propose that NCAM, which is highly expressed in NPCs during the neurogenic period,  
340 promotes neurogenesis and suppresses gliogenesis (**Fig. 9**).

341 We provide evidence that NCAM regulates the proliferation and differentiation of NPCs  
342 via its binding to profilin2, which interacts directly with NCAM140 intracellular domain.  
343 NCAM180, NCAM120 and the soluble extracellular domain of NCAM also co-  
344 immunoprecipitate with profilin2, most likely due to their homophilic binding to NCAM140  
345 (Soroka et al., 2003). Surprisingly, NCAM180 does not bind directly to profilin2 although  
346 NCAM140 and NCAM180 comprise overlapping amino acid sequences in their intracellular  
347 domains, suggesting that NCAM180 is conformationally restricted from its interaction with  
348 profilin2. NCAM180 accumulates at contacts between cells, and a reduction in its association  
349 with the actin filament-remodeling proteins may be important for stabilization of cell contacts  
350 (Pollerberg et al., 1986). In contrast, NCAM140 is more involved in dynamic cell interactions.  
351 NCAM120 and NCAM140 are the predominant forms of NCAM in NPCs at E14 (**Fig. 6K** and  
352 (Prodromidou et al., 2014) whereas NCAM180 and NCAM140 are the major isoforms in

353 neurons (Korshunova et al., 2007). Consistently, NCAM140, but not its mutant with abolished  
354 binding to profilin2, rescues abnormal proliferation and differentiation of NPCs caused by  
355 NCAM depletion in NPCs. Thus, the combined observations suggest that NCAM-dependent  
356 regulation of neuronal development is fine-tuned by the temporally specific expression patterns  
357 of NCAM isoforms.

358 Regulation of actin dynamics by profilin1 and -2 require both discrete and cooperative  
359 activities. One example is that expression of profilin1 rescues the loss of spines (but not  
360 dendritic complexity) caused by profilin2 knockdown (Michaelsen et al., 2010). Indeed,  
361 profilin2-deficient neurons show an initial, transient increase in the number of sprouting  
362 neurites, which may be due to the compensatory function of profilin1 (Da Silva et al., 2003).  
363 In addition, NCAM-depleted NPCs exhibit reduced profilin2 levels. Thus, the transient nature  
364 of abnormalities in NPCs observed in NCAM cKO cells may be due to a functional  
365 compensation by profilin1. We herein show that profilin2 is required for NCAM-regulated NPC  
366 proliferation and differentiation, which depends on binding of NCAM to profilin2 which  
367 exhibits an expression profile similar to that of NCAM in NPCs during brain development.  
368 Acute profilin2 knockdown in cultured NPCs results in a phenotype being comparable to that  
369 of NCAM-deficient NPCs, suggesting that profilin2 and NCAM have similar roles in the  
370 developing cerebral cortex. Consistently, profilin2-deficient mice are hyperactive and show  
371 increased exploratory behavior (Pilo Boyl et al., 2007), thus partly resembling behavioral  
372 abnormalities in NCAM-deficient mice. Profilins bind to various ligands and are involved in  
373 distinct cellular processes, such as membrane and vesicle trafficking, endocytosis, and receptor  
374 clustering. Profilins are also found in the cell nucleus, where they may be involved in chromatin  
375 remodeling and transcription (Witke, 2004). Further research is required for a more holistic  
376 understanding of the role of profilin2 during cortical development.

377 NCAM is the major carrier of the linear homopolymer  $\alpha$ 2-8-N acetylneuraminic acid

378 (PSA), which plays a prominent role in regulation of migration and differentiation of progenitor  
379 cells during postnatal brain development (Angata et al., 2007), as well as in the adult brain  
380 (Burgess et al., 2008). We did not detect NCAM-PSA in E14 NPCs (**Fig. 6K**), which is in  
381 accordance with previous reports showing that NCAM is not polysialylated during the early  
382 phases of neurogenesis in the developing brain (Bonfanti, 2006; Prodromidou et al., 2014; Seki  
383 and Arai, 1991). This in turn suggests that NCAM rather than PSA plays a key role at these  
384 early development stages.

385 Our observations also indicate that NCAM regulates corticogenesis by modulating actin  
386 dynamics. NCAM deficiency leads to reduced actin polymerization, elongated progenitor cell  
387 shape, and decreased mitosis (**Fig. 9**). Remodeling of the actin cytoskeleton during mitosis is  
388 necessary for formation of rounded cells with increased cortical rigidity (Heng and Koh, 2010;  
389 Luxenburg et al., 2011). At the end of mitosis, actin rearranges at cleavage furrows and  
390 contributes to formation of the contractile ring, which is crucial for cytokinesis. Another mitotic  
391 event requiring actin dynamics is centrosome separation, which depends on the flow of  
392 submembrane actin and the myosin network (Heng and Koh, 2010). The modulation of cell  
393 shape changes in coordination with cell cycle progression is a pre-requisite for the acquisition  
394 of appropriate cell fates and the transformation of proliferating, undifferentiated progenitors  
395 into fully differentiated, functional cells (Cremisi et al., 2003). We show that NCAM-dependent  
396 actin remodeling promotes neurogenesis, but suppresses gliogenesis.

397 The actin cytoskeleton is also involved in transcription control (Miralles and Visa, 2006).  
398 Actin is a component of the transcription apparatus, chromatin-remodeling complexes, and  
399 RNA-processing machinery (Miralles and Visa, 2006). Our data show that deficiency in NCAM  
400 results in inhibited neurogenesis and enhanced gliogenesis from NPCs, suggesting a role for  
401 NCAM in the control of the neurogenic-gliogenic switch. This cell fate programming comprises  
402 specific signaling pathways, such as JAK-STAT, Notch, BMP, and MEK-ERK-dependent

403 signaling to activate transcription factors (Miller and Gauthier, 2007). Whether NCAM  
404 regulates transcription by modulating actin dynamics is a question for future investigation.

405 In the developing brain, neurons are generated first, while gliogenesis is suppressed during  
406 the neurogenic period. Astroglialogenesis is induced later, after neurons had been generated in  
407 sufficient numbers (Sloan and Barres, 2014). Astrocytes, in turn, guide appropriate neurite and  
408 synapse development (Jacobs and Doering, 2010; Sloan and Barres, 2014). This temporal  
409 sequence of coordinated generation of neurons and astrocytes is required for proper  
410 establishment of neural circuits. Perturbations in the temporally orchestrated generation of  
411 neurons and glia may cause impaired neuronal development and synaptic plasticity, leading to  
412 neurodevelopmental disorders, such as Down syndrome, autism spectrum disorders and  
413 “RASopathies” (Jacobs and Doering, 2010; Sloan and Barres, 2014; Zdaniuk et al., 2011), the  
414 latter including Noonan (Tartaglia et al., 2001), neurofibromatosis-1 (Hegedus et al., 2007),  
415 costello (Paquin et al., 2009), and cardiofaciocutaneous syndrome (Urosevic et al., 2011).  
416 Despite a broad spectrum of clinical manifestations, these syndromes share some degree of  
417 mental impairment and precocious astrogenesis (Sloan and Barres, 2014). In turn, NCAM-  
418 deficient mice display hyperactivity, increased aggression, learning deficits, and impaired nest  
419 building behaviors (Cremer et al., 1994; Stork et al., 1997; Stork et al., 2000; Stork et al., 1999;  
420 Vicente et al., 1997).

421 In the mature brain, NCAM is involved in regulation of the number, structure, and  
422 molecular composition of synapses, synaptic vesicle recycling, synaptic plasticity, learning  
423 (Bukalo et al., 2004; Puchkov et al., 2011; Shetty et al., 2013; Sytnyk et al., 2006), and behavior  
424 (Brandewiede et al., 2014; Kohl et al., 2013; Pillai-Nair et al., 2005; Stork et al., 1999). By  
425 regulating actin polymerization (Schluter et al., 1997), profilin2 also plays a role in modulation  
426 of synaptic vesicle exocytosis, neuronal excitability (Pilo-Boyl et al., 2007), spine density,  
427 dendritic complexity (Da Silva et al., 2003; Michaelsen et al., 2010; Witke et al., 1998),

428 learning, and memory consolidation (Lamprecht et al., 2006). Whether NCAM and profilin2  
429 co-operate in regulation of synapse formation and function is, however, unknown and remains  
430 a question for further investigation.

431 Our study suggests that abnormalities in temporal NPC fate decision can contribute to the  
432 pathophysiology of neurodevelopmental diseases associated with abnormal function of NCAM.  
433 Understanding the molecular mechanisms underlying these abnormalities may help to design  
434 future strategies aimed at correcting neural differentiation in the affected brain.

435 **Materials and methods**

436 **Antibodies**

437 The following antibodies were used for immunofluorescence analysis: goat anti-Sox2  
438 (1:150, Santa Cruz Biotechnology, sc-17320, RRID: AB\_2286684), mouse anti-BrdU (1:300,  
439 Covance, MMS-139S, RRID: AB\_10719257), mouse anti- $\beta$ III-tubulin (1:500, Tuj1, Sigma-  
440 Aldrich, T5076, RRID: AB\_532291), mouse anti-profilin2 (1:100, Proteintech, 60094-2-Ig,  
441 RRID: AB\_2163215), rabbit anti-NCAM (1:300, Alomone, ANR-041, RRID: AB\_2756690),  
442 rabbit anti-NCAM (1:200, Thermo, 701379, RRID: AB\_2532477), rabbit anti-Pax6 (1:300,  
443 Covance, PRB-278P, RRID: AB\_291612), rabbit anti-Tbr1 (1:300, Abcam, ab3190, RRID:  
444 AB\_2238610), rabbit anti-Tbr2 (1:300, Abcam, ab23345, RRID: AB\_778267), rabbit anti-  
445 Olig2 (1:300, Abcam, ab109186, RRID: AB\_10861310), rabbit anti-GFAP (1:500, Millipore,  
446 MAB360, RRID: AB\_11212597), rabbit anti-PH3 (1:300, Millipore, 06-570, RRID:  
447 AB\_310177), rabbit anti-Ki67 (1:100, Thermo, PA5-19462, RRID: AB\_10981523), rabbit anti-  
448 Ctip2 (1:300, Abcam, ab28448, RRID: AB\_1140055), rabbit anti-Cux1 (1:100, Santa Cruz  
449 Biotechnology, sc-13024, RRID: AB\_2261231), rabbit anti-BLBP (1:100, Abcam, ab32423,  
450 RRID: AB\_880078), mouse anti-A2B5 (1:300, Thermo, MA1-90445, RRID: AB\_1954783)  
451 and rabbit anti-cleaved caspase3 (1:300, Cell Signaling, 9661, RRID: AB\_2341188). Rabbit  
452 anti-NCAM (Alomone, ANR-041, RRID: AB\_2756690) and rabbit anti-profilin2 (Abcam,  
453 ab174322, RRID: AB\_2783646) antibodies were used for immunoprecipitation and Western  
454 blot analysis. Chicken anti-NCAM antibody (Li et al., 2013) was used to assay NPC  
455 proliferation and differentiation. Rat anti-NCAM (BD Pharmingen, 556323, RRID:  
456 AB\_396361) antibody was used for Western blot analysis and ELISA. Mouse anti-actin  
457 (Sigma-Aldrich, A5441, RRID: AB\_476744) antibody was used for immunofluorescence and  
458 Western blot analysis. Mouse anti- $\gamma$ -tubulin antibody (Sigma-Aldrich, T6557, RRID:  
459 AB\_477584) was used for Western blot analysis. Non-immune mouse immunoglobulin (IgG)

460 and horseradish peroxidase (HRP)-coupled secondary antibodies were purchased from Sigma-  
461 Aldrich. Secondary antibodies conjugated with Alexa fluorophores 488, 555 or 647 were  
462 purchased from Invitrogen. Acti-stain™ 670 Fluorescent phalloidin (Cytoskeleton, PHDN1-A)  
463 was used for F-actin staining. Alexa Fluor 594 conjugated deoxyribonuclease I (Molecular  
464 Probes, D12372) was used for G-actin staining.

465

## 466 **Mice**

467 Homozygous NCAM-floxed mice (NCAMff<sup>+/+</sup>; (Bukalo et al., 2004) were crossed with  
468 Nestin-cre transgenic mice (Jackson Laboratory, 003771) to generate conditionally NCAM-  
469 deficient (NCAMff<sup>+/+</sup>cre<sup>+/-</sup>, NCAM cKO) mice and their control littermates (referred to as  
470 NCAMff<sup>+/+</sup>cre<sup>-/-</sup> or NCAMff<sup>+/-</sup>cre<sup>-/-</sup>). Successful mating was verified by the presence of a  
471 vaginal plug. Observation date of the plug was considered E0.5. Mice had been backcrossed  
472 with C57BL/6J mice for more than 10 generations and were maintained on the C57BL/6J  
473 background thereafter. All experimental procedures were in accordance with ARRIVE (Animal  
474 Research: Reporting of *In Vivo* Experiments) guidelines and were approved by the Institutional  
475 Animal Care and Use Committee of Soochow University.

476

## 477 **DNA constructs, protein expression and ELISA**

478 Sequences of the intracellular domain of rat NCAM140 (NCAM140ICD) and NCAM180  
479 (NCAM180ICD) were subcloned from prokaryotic expression pQE30-NCAM140ICD and  
480 pQE30-NCAM180ICD plasmids (Li et al., 2013) into pET29b-His vector (Novagen, 69872).  
481 The pET29b-NCAM140ICD was used as a template to produce the mutant NCAM140ICD  
482 expression vector, pET29b-muNCAM140ICD, by site-directed mutagenesis with CTG  
483 encoding L<sup>749</sup> mutated into GCG, and TGT encoding C<sup>750</sup> mutated into TCT. Primers for  
484 mutagenesis were TGCATCGCTGTAAACGCGTCTGGCAAAGCTGGG (forward), and

485 CATGAGCAGGCCACACTTGTTTCAGGAAGTAGCAGG (reverse). The pET29b-profilin2  
486 was synthesized by Takara (Dalian, China). The profilin2 sequence was subcloned into a  
487 pCDH-EF1-MCS-T2A-copGFP vector. The pEX4-siRNA-resistant-profilin2 plasmid was  
488 generated by Genepharma (Shanghai, China) using the pEX4-profilin2 as a template for three  
489 synonymous mutations on the profilin2 siRNA recognition sequence with  
490 CATCACGCCAGTAGAAATA mutated into CATTACTCCAGTTGAAATA. All plasmid  
491 constructs were verified by sequencing. Prokaryotic pET29b-NCAM140ICD, pET29b-  
492 muNCAM140ICD, pET29b-NCAM180ICD, and pET29b-profilin2 plasmids were transformed  
493 and expressed in *E. coli* strain BL21, and corresponding recombinant proteins were purified by  
494 Ni-NTA chromatography (Qiagen, 30210).

495 Profilin2 (100 µg/ml) was immobilized overnight at 4°C on a polyvinylchloride surface in  
496 96-well ELISA plates (Corning, 2595). Then, the wells were washed three times with PBST  
497 (PBS with 0.1% Tween 20, pH 7.4) and blocked with 3% BSA in carbonate buffer (35 mM  
498 NaHCO<sub>3</sub> and 15 mM Na<sub>2</sub>CO<sub>3</sub>, pH 9.6) at 37°C for 2 h. Thereafter, increasing concentrations  
499 (0.1-12.5 µM) of recombinant NCAM140ICD, NCAM180ICD or muNCAM140ICD (in  
500 PBST) were applied at 37°C for 2 h. After three washes, the wells were incubated with NCAM  
501 monoclonal antibodies (0.5 µg/ml) for 1.5 h at 37°C. Following five washes with PBST, HRP-  
502 conjugated secondary antibodies were applied for 1 h at 37°C. After five washes, protein  
503 binding was analyzed by adding the HRP substrate, tetramethylbenzidine reagent (Pierce,  
504 34021). The reaction was terminated with 2 M H<sub>2</sub>SO<sub>4</sub> and ODs were measured at 450 nm using  
505 a plate reader (Thermo, 51119000). Biotinylated peptides comprising amino acid sequences  
506 729-750, 748-763, 756-770, 764-777, 766-810 of mouse NCAM140, <sup>745</sup>IAV NLC GKA<sup>753</sup>  
507 peptide comprising the profilin2 binding site, and mutated <sup>745</sup>IAV NAS GKA<sup>753</sup> and <sup>745</sup>IAV  
508 QAC GKA<sup>753</sup> peptides were synthesized by SciLight Peptide (Beijing, China). All constructs  
509 were incubated with substrate-coated profilin2 and detected by HRP-coupled NeutrAvidin

510 (Thermo, 31030).

511

## 512 **RNA interference**

513 The siProfilin2-399 (CAUCACGCCAGUAGAAAUATT), siProfilin2-527  
514 (CAAUGGACAUCCGGACAAATT), siNCAM (GUUGGAGAGUCCAAAUUCUTT) and  
515 the NC (UUCUCCGAACGUGUCACGUTT) were synthesized by Genepharma (Shanghai,  
516 China). The shProfilin2 was constructed by Genechem (Shanghai, China) by inserting the same  
517 target sequence as siProfilin2-399 into the GV102 vector. To confirm siProfilin2 efficacy,  
518 Neuro-2a cells (ATCC, CCL-131™) were transfected with siRNA/shRNA using Lipofectamine  
519 2000 according to the manufacturer's instructions (Invitrogen, 11668030). Mouse embryonic  
520 fibroblasts (MEFs, ATCC, SCRC-1008™) were transfected with siRNA using Lipofectamine  
521 2000. The profilin2/NCAM knockdown efficacy was verified by Western blot analysis of cell  
522 lysates. Cultured NPCs were transfected with 20 pmol of RNA per cuvette using the Amaxa®  
523 Nucleofector system (Lonza, VPG-1004) according to the user's manual.

524

## 525 **Culture and transfection of NPCs**

526 NPCs were obtained from the telencephalic lateral ventricle walls of E14 embryos and  
527 cultured in DMEM/F12 culture medium (Gibco, 11320033) supplemented with 2% B27  
528 (Gibco, 17504044), 20 ng/ml basic fibroblast growth factor (bFGF, Peprotech, 96-450-33), and  
529 20 ng/ml epidermal growth factor (EGF, Peprotech, 315-09) as described (Ma et al., 2008). For  
530 differentiation, NPCs were cultured in DMEM/F12 medium containing 2% B27 and 0.5% fetal  
531 calf serum (Gibco) without EGF and bFGF for 5-7 days.

532 For NCAM antibody incubation experiments, NCAM antibodies (10 µg/ml) were added  
533 to the culture medium and replenished every 24 h. The medium was changed every 48 h.

534 Transfection of cultured NPCs was performed using the Amaxa® Nucleofector system

535 (Lonza, VPG-1004) according to the user's manual.

536

### 537 **Lentiviral transduction**

538 Lentivirus constructs containing full-length wild type or mutated mouse NCAM140 genes  
539 were generated by Genechem (Shanghai, China) in an Ubi-MCS-3FLAG-SV40-EGFP-IRES-  
540 puromycin (GV358) vector comprising ubiquitin, SV40, and CMV promoters. Cultured NPCs  
541 and MEFs were transduced with  $1 \times 10^8$  TU/ml lentivirus following the manufacturer's  
542 instructions and thereafter maintained for 2-4 d.

543

### 544 **BrdU labeling**

545 For analysis of proliferation *in vivo*, pregnant mice were intraperitoneally injected with  
546 BrdU (50 mg/kg, Sigma-Aldrich, B5002) at different embryonic stages (E12, E14, E16 and  
547 E18) and sacrificed 30 min thereafter (Wu et al., 2017). For determination of the cell cycle exit,  
548 BrdU (100 mg/kg) was intraperitoneally injected into pregnant mice, and mice were sacrificed  
549 18 h after injection. The cell cycle exit index was calculated as  $\text{BrdU}^+\text{Ki67}^-/\text{total BrdU}^+$  cells  
550 (the percentage of cells exiting the cell cycle). The length of S-phase of the cell cycle was  
551 calculated as  $\text{BrdU}^+\text{Ki67}^+/\text{total Ki67}^+$  cells.

552 For pulse-chase labeling of newborn cells, pregnant mice were intraperitoneally injected  
553 with BrdU (100 mg/kg) at E11.5, E14.5, E15.5 and sacrificed at E18, or injected with BrdU at  
554 E16.5 and sacrificed at P2. Quantification of birth-dated neurons was performed by calculating  
555 the percentages of  $\text{BrdU}^+$  layer-specific neuronal marker<sup>+</sup> cells/total layer-specific neuronal  
556 marker<sup>+</sup> (Tbr1<sup>+</sup>, Ctip2<sup>+</sup> or Cux1<sup>+</sup>) cells. Quantitation of birth-dated oligodendrocytes was  
557 performed by calculating the percentage of  $\text{Olig2}^+\text{BrdU}^+$  cells/total  $\text{Olig2}^+$  cells. Quantification  
558 of birth-dated astrocytes was calculated as the numbers of  $\text{GFAP}^+\text{BrdU}^+$  cells along the  
559 dorsolateral VZ.

560 To investigate NPC proliferation *in vitro*, cells were cultured for 4-5 h in NPC culture  
561 medium supplemented with 10  $\mu$ M BrdU.

562

### 563 **Immunohistochemistry and image analysis**

564 Immunohistochemistry was performed as described elsewhere (Wu et al., 2017). Briefly,  
565 pregnant mice were sacrificed and the fetuses were removed from the uterus. Fetal brains were  
566 fixed in 4% formaldehyde in PBS (pH 7.3) for 24 h at 4 °C followed by sequential dehydration  
567 using 15% and 30% sucrose in PBS. Coronal sections (14  $\mu$ m thick) were sectioned with a  
568 cryostat (Leica CM1950), and washed 3 times with PBS before blocking in 10% donkey serum  
569 in 0.1% Triton X-100 in PBS for 1 h at room temperature. Primary antibodies were applied in  
570 the blocking solution for 16 h at 4°C, followed by 3 washes in PBS. Secondary antibodies were  
571 incubated in the blocking solution for 1 h at room temperature. Sections were then washed, air-  
572 dried, and mounted using DAPI Fluoromount-G (Southern Biotech, 0100-20). Fluorescence  
573 images were acquired with a Carl Zeiss Microscope Axio Scope A1 (20x objective lenses,  
574 acquisition software ZEN 2.6 (blue edition)) or a confocal laser scanning microscope LSM700  
575 (20x, 40x, 40x oil or 63x oil objective lenses, acquisition software ZEN 2012) at room  
576 temperature. NCAM and profilin2 immunofluorescence intensity was quantified by Image J.  
577 Identical telencephalon cortical regions from littermates of control and NCAM cKO mice (five  
578 sections per brain) were analyzed. NCAM/profilin2 immunofluorescence intensity was  
579 calculated as NCAM/profilin2 immunofluorescence intensity in different cortical regions in  
580 relation to the whole dorsal cortices. The average fluorescence density of NCAM/profilin2 was  
581 obtained by calculating the fluorescence density within a 250  $\mu$ m<sup>2</sup> area in different cortical  
582 layers. Cortical cells were counted in regions as described previously (Cappello et al., 2006;  
583 Seuntjens et al., 2009). In brief, Tbr1<sup>+</sup> and ctip2<sup>+</sup> cells were counted in the medial brain as they  
584 distribute evenly in layer VI and V of the dorsal cortex; Cux1<sup>+</sup> and Olig2<sup>+</sup> cells in the lateral

585 brain regions where they appear first; and GFAP<sup>+</sup> cells in the dorsal pallium adjacent to the VZ  
586 where they reside. The total GFAP<sup>+</sup> intensity was counted in VZ/SVZ because there are few  
587 GFAP<sup>+</sup> cells appearing in the wild type at E16, and the earlier appearing GFAP<sup>+</sup> cells do not  
588 distribute evenly in the VZ/SVZ (**Fig. S5**). Proliferating (i.e., BrdU<sup>+</sup>, Ki67<sup>+</sup>, PH3<sup>+</sup>), Tbr2<sup>+</sup>,  
589 Pax6<sup>+</sup>, Tbr1<sup>+</sup>, and Ctip2<sup>+</sup> cells were counted in 100 μm x 250 μm areas in the dorsal pallium  
590 perpendicular to the VZ (red rectangle), and numbers of Cux1<sup>+</sup> and Olig2<sup>+</sup> cells were counted  
591 in 100 μm x 250 μm areas of the dorsolateral pallium (blue rectangle). Numbers of caspase3<sup>+</sup>  
592 cells were determined in the entire hemi-telencephalon cortex. The GFAP expression per unit  
593 area (150 μm x 150 μm) was measured in the dorsolateral pallium adjacent to VZ using ImageJ  
594 (purple square).

595 For cortical neuron distribution analysis, the maximum migration of neonatal cortical  
596 neurons was measured as the vertical distance from VZ to the destination of different layers  
597 using ImageJ. The length of the entire cortical layers perpendicular to the VZ was measured  
598 using ImageJ and defined as total cortical length. The distribution of layer-specific marker<sup>+</sup>  
599 (Tbr1<sup>+</sup>, Ctip2<sup>+</sup> or Cux1<sup>+</sup>) neuron was quantified by calculating maximum migration distance of  
600 each type of neurons/total cortical length (shown by schematic diagram in **Fig. S3**).

601

## 602 **Yeast two-hybrid screening**

603 Yeast two-hybrid screening was performed with the ProQuest Two-Hybrid system  
604 (Invitrogen, 10835) in *Saccharomyces cerevisiae* strain MaV203 following the manufacturer's  
605 protocol. The DNA fragment encoding the intracellular domain of mouse NCAM140 was used  
606 as bait.

607

## 608 **Co-immunoprecipitation**

609 Lysates of brains from newborn C57BL/6J mice were prepared using ice-cold lysis buffer

610 (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% Triton X-100, 1% sodium deoxycholate, 0.5%  
611 SDS, 2 mM EDTA, and protease inhibitor cocktail (Roche, 11697498001)). Lysates were  
612 centrifuged for 10 min at 15,000 g and 4°C, cleared with protein A/G-agarose beads (Santa  
613 Cruz Biotechnology, sc-2003, RRID: AB\_10201400), and incubated with corresponding  
614 antibodies or, for negative control, non-immune IgG at 4°C overnight. Antibody/protein  
615 complexes were collected by incubating lysates with protein A/G-agarose beads for 3 h at 4°C,  
616 pelleting the beads and washing in PBS. Proteins were eluted with 2x SDS sample buffer by  
617 boiling the beads for 10 min and subjected to Western blot analysis.

618

### 619 **Quantitative real-time PCR**

620 Total RNA was extracted from cultured NPCs using Trizol Reagent (Invitrogen,  
621 15596018). Reverse transcription reactions were performed with the EasyScript<sup>®</sup> One-Step  
622 gDNA Removal and cDNA Synthesis SuperMix kits (Transgen Biotech, AE311-02). PCR  
623 primers were: forward 5'-GCCTATACGTTGATGGTGACTG-3', reverse 5'-  
624 ACAAAGACCAAGACTCTCCCG-3' for profilin2, forward 5'-  
625 GACAGAACCCGAAAAGGGC-3', reverse 5'-GTTGGGGACCGTCTTGACTT-3' for  
626 NCAM, forward 5'-AGGTCGGTGTGAACGGATTTG-3', reverse 5'-  
627 TGTAGACCATGTAGTTGAGGTCA-3' for GAPDH. The reaction procedure was conducted  
628 at 94°C, 15 min (1 cycle); 95°C, 30 s; 55°C, 30 s; 72 °C, 60 s (30 cycles), and 72°C, 8 min (1  
629 cycle).

630

### 631 **Immunocytochemistry and image analysis**

632 Immunocytochemistry was performed as described elsewhere (Ma et al., 2008). Briefly,  
633 cells were fixed in 4% paraformaldehyde in PBS for 15 min, permeabilized by 0.1% Triton X-  
634 100 in PBS for 5 min, and blocked by 10% donkey serum in 0.1% Triton X-100 in PBS for 1 h

635 at room temperature. Cells were incubated with appropriate dilutions of primary antibodies in  
636 the blocking solution at 4°C overnight. Cells were then rinsed with PBS, and incubated with  
637 corresponding secondary antibodies in the blocking solution for 1 h at room temperature. The  
638 culture was rinsed three times with PBS, and counterstained with DAPI Fluoromount-G  
639 (Southern Biotech, 0100-20). To detect BrdU in cultured NPCs, cells were treated with 2 N HCl  
640 for 10 min at 37°C. The proportion of proliferating NPCs was quantified as the numbers of  
641 BrdU<sup>+</sup> cells divided by the total number of DAPI<sup>+</sup> cells. To estimate differentiation into  
642 neurons, astrocytes and oligodendrocytes, numbers of Tuj1<sup>+</sup>, GFAP<sup>+</sup> or O4<sup>+</sup> cells, respectively,  
643 were divided by the total number of DAPI<sup>+</sup> cells. Proliferation and differentiation of profilin2  
644 siRNA-transfected NPCs were quantified from random images of areas containing cultured  
645 cells. The proportion of target cells was quantified as the numbers of BrdU<sup>+</sup>, Tuj1<sup>+</sup>, GFAP<sup>+</sup> or  
646 O4<sup>+</sup> cells divided by the total number of DAPI<sup>+</sup> cells in the same field. Proliferation and  
647 differentiation of NPCs transfected with plasmids encoding profilin2, NCAM and mutNCAM  
648 were quantified from images of areas captured from top-to-bottom and left-to-right across the  
649 entire coverslip. The proportion of target cells was quantified as the numbers of BrdU<sup>+</sup>GFP<sup>+</sup>,  
650 Tuj1<sup>+</sup>GFP<sup>+</sup>, GFAP<sup>+</sup>GFP<sup>+</sup> cells divided by the total number of GFP<sup>+</sup> cells in the same coverslip.  
651 Each experiment was performed in independent triplicates.

652

### 653 **F-actin and G-actin analysis**

654 F- and G-actin levels were analyzed by Western blot using an F-actin/G-actin *in vivo* assay  
655 kit (Cytoskeleton, BK037). Briefly, cultured NPCs were lysed with pre-warmed F-actin  
656 stabilization buffer (50 mM PIPES buffer, pH 6.9, 50 mM NaCl, 5 mM MgCl<sub>2</sub>, 5 mM EGTA,  
657 5% (v/v) glycerol, 0.1% Nonidet P40, 0.1% Triton X-100, 0.1% Tween 20, 0.1% β-mercapto-  
658 ethanol) at 37°C for 10 min. Samples were centrifuged at 100,000 g for 1 h at 37°C.  
659 Supernatants containing G-actin were separated from the pellets containing F-actin and placed

660 on ice. The pellets were resuspended in the same volume as the supernatants using ice-cold  
661 water containing 1  $\mu$ M cytochalasin D and incubated on ice for 1 h by pipetting up and down  
662 every 15 min to dissociate F-actin. Equal amounts of protein from each sample were subjected  
663 to Western blot analysis with anti-actin antibody with  $\gamma$ -tubulin serving as a control.

664 To analyze levels of G- and F-actin by microscopy, NPCs were co-stained by phalloidin  
665 (for F-actin) and deoxyribonuclease I (for G-actin). GFP-positive cells were outlined, the F-  
666 actin and G-actin labelling intensities were measured by Image Pro-plus 6.4 software (Media  
667 Cybernetics), and the ratio of F-actin/G-actin was calculated.

668

### 669 **CSI analysis**

670 The CSI analysis was performed as described elsewhere (Thakar et al., 2009). The coronal  
671 cortical sections at E12 were immunostained for actin with DAPI counterstaining to visualize  
672 cells and chromatin. Mitotic NPCs at metaphase and anaphase were identified by chromosome  
673 morphology at the VZ surface, selected, and analyzed (Haydar et al., 2003; Luxenburg et al.,  
674 2011). Cell boundaries were outlined with ImageJ. Cell area and perimeter were determined,  
675 and the CSI was calculated as follows:  $CSI = 4\pi \cdot \text{area}/(\text{perimeter})^2$ . The CSI assumes values  
676 between 1 (circular shape) and 0 (elongated, linear morphology) (Thakar et al., 2009).

677

### 678 **Statistical analysis**

679 Data were collected from at least three independent experiments ( $n \geq 3$ ) or at least three  
680 pairs of NCAM cKO mice and control littermates ( $n \geq 3$ , five slices from each animal). Values  
681 are presented as means  $\pm$  SEM. Data distribution was checked by Kolmogorov-Smirnov test.  
682 Statistical difference was tested by Student's t test, one-way ANOVA, or two-way ANOVA (for  
683 normal distribution data), Mann-Whitney or Kruskal-Wallis test (for non-normally distributed  
684 data) with appropriate *post-hoc* analysis using SPSS 22.0 software (all two-sided).  $P < 0.05$  was

685 considered statistically significant (\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ).

686

687 **Online supplemental material**

688 Fig. S1. Expression of NCAM and profilin2 in the developing cerebral cortex.

689 Fig. S2. NCAM deficiency does not lead to increased NPC apoptosis during embryonic  
690 development.

691 Fig. S3. NCAM deficiency does not affect the distribution of neonatal cortical neurons in the  
692 coronal plane.

693 Fig. S4. Profilin2 expression is downregulated specifically by profilin2 RNA interference.

694 Fig. S5. Schematic diagram showing areas chosen for quantification of cells in imaging  
695 analysis.

696 **Acknowledgments**

697 This work was supported by National Natural Science Foundation of China (81300985,  
698 81870897, 81671111, 81601111), the Natural Science Foundation of Liaoning Province (2019-  
699 MS-075), LiaoNing Revitalization Talents Program (XLYC1807124), Dalian Technology  
700 Innovation Program (2019J13SN109), Natural Science Foundation of Jiangsu Province  
701 (BK20181436), Guangdong Key Project in "Development of new tools for diagnosis and  
702 treatment of Autism " (2018B030335001), Priority Academic Program Development of Jiangsu  
703 Higher Education Institution (PAPD), the Suzhou Clinical Research Center of Neurological  
704 Disease (Szzx201503), Jiangsu Provincial Medical Key Discipline Project (ZDXKB2016022)  
705 and Jiangsu Provincial Special Program of Medical Science (BL2014042), Jiangsu Key  
706 Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases (BM2013003),  
707 Health Commission of Dalian (1711014) and the Li Kashing Foundation.

708 The authors declare no competing financial interests.

709 Author contributions: M. Schachner, V. Sytnyk, J. Boltze, Q.-H. Ma, and S. Li conceived  
710 and designed the experiments. R. Huang, D.-J. Yuan, S. Li, X.-S. Liang, Y. Gao, X.-Y. Lan, H.-  
711 M. Qin, and G.-Y. Xu performed the experiments and analyzed the data. R. Huang, Y.-F. Ma,  
712 V. Sytnyk, M. Schachner, J. Boltze, H.-M. Qin, Q.-H. Ma and S. Li wrote the paper.

713 **References**

- 714 Amoureux, M.C., B.A. Cunningham, G.M. Edelman, and K.L. Crossin. 2000. N-CAM binding  
715 inhibits the proliferation of hippocampal progenitor cells and promotes their  
716 differentiation to a neuronal phenotype. *J Neurosci.* 20:3631-3640.
- 717 Angata, K., V. Huckaby, B. Ranscht, A. Terskikh, J.D. Marth, and M. Fukuda. 2007. Polysialic  
718 acid-directed migration and differentiation of neural precursors are essential for mouse  
719 brain development. *Mol Cell Biol.* 27:6659-6668.
- 720 BaracsKay, K.L., G.J. Kidd, R.H. Miller, and B.D. Trapp. 2007. NG2-positive cells generate  
721 A2B5-positive oligodendrocyte precursor cells. *Glia.* 55:1001-1010.
- 722 Bonfanti, L. 2006. PSA-NCAM in mammalian structural plasticity and neurogenesis. *Prog*  
723 *Neurobiol.* 80:129-164.
- 724 Boutin, C., B. Schmitz, H. Cremer, and S. Diestel. 2009. NCAM expression induces  
725 neurogenesis in vivo. *Eur J Neurosci.* 30:1209-1218.
- 726 Brandewiede, J., O. Stork, and M. Schachner. 2014. NCAM deficiency in the mouse forebrain  
727 impairs innate and learned avoidance behaviours. *Genes Brain Behav.* 13:468-477.
- 728 Brennaman, L.H., and P.F. Maness. 2010. NCAM in neuropsychiatric and neurodegenerative  
729 disorders. *Adv Exp Med Biol.* 663:299-317.
- 730 Bukalo, O., N. Fentrop, A.Y. Lee, B. Salmen, J.W. Law, C.T. Wotjak, M. Schweizer, A.  
731 Dityatev, and M. Schachner. 2004. Conditional ablation of the neural cell adhesion  
732 molecule reduces precision of spatial learning, long-term potentiation, and depression  
733 in the CA1 subfield of mouse hippocampus. *J Neurosci.* 24:1565-1577.
- 734 Burgess, A., S.R. Wainwright, L.S. Shihabuddin, U. Rutishauser, T. Seki, and I. Aubert. 2008.  
735 Polysialic acid regulates the clustering, migration, and neuronal differentiation of  
736 progenitor cells in the adult hippocampus. *Dev Neurobiol.* 68:1580-1590.
- 737 Cappello, S., A. Attardo, X. Wu, T. Iwasato, S. Itohara, M. Wilsch-Brauninger, H.M. Eilken,

738 M.A. Rieger, T.T. Schroeder, W.B. Huttner, C. Brakebusch, and M. Gotz. 2006. The  
739 Rho-GTPase cdc42 regulates neural progenitor fate at the apical surface. *Nat Neurosci.*  
740 9:1099-1107.

741 Chakraborty, J., M. Pandey, A.K. Navneet, T.A. Appukuttan, M. Varghese, S.C. Sreetama, U.  
742 Rajamma, and K.P. Mohanakumar. 2014. Profilin-2 increased expression and its altered  
743 interaction with beta-actin in the striatum of 3-nitropropionic acid-induced Huntington's  
744 disease in rats. *Neuroscience.* 281:216-228.

745 Cremer, H., R. Lange, A. Christoph, M. Plomann, G. Vopper, J. Roes, R. Brown, S. Baldwin,  
746 P. Kraemer, S. Scheff, and et al. 1994. Inactivation of the N-CAM gene in mice results  
747 in size reduction of the olfactory bulb and deficits in spatial learning. *Nature.* 367:455-  
748 459.

749 Cremisi, F., A. Philpott, and S. Ohnuma. 2003. Cell cycle and cell fate interactions in neural  
750 development. *Curr Opin Neurobiol.* 13:26-33.

751 Da Silva, J.S., M. Medina, C. Zuliani, A. Di Nardo, W. Witke, and C.G. Dotti. 2003.  
752 RhoA/ROCK regulation of neuritogenesis via profilin IIA-mediated control of actin  
753 stability. *J Cell Biol.* 162:1267-1279.

754 Dehay, C., and H. Kennedy. 2007. Cell-cycle control and cortical development. *Nat Rev*  
755 *Neurosci.* 8:438-450.

756 Di Nardo, A., R. Gareus, D. Kwiatkowski, and W. Witke. 2000. Alternative splicing of the  
757 mouse profilin II gene generates functionally different profilin isoforms. *J Cell Sci.* 113  
758 Pt 21:3795-3803.

759 Dietrich, J., M. Noble, and M. Mayer-Proschel. 2002. Characterization of A2B5+ glial  
760 precursor cells from cryopreserved human fetal brain progenitor cells. *Glia.* 40:65-77.

761 Feng, L., M.E. Hatten, and N. Heintz. 1994. Brain lipid-binding protein (BLBP): a novel  
762 signaling system in the developing mammalian CNS. *Neuron.* 12:895-908.

763 Gal, J.S., Y.M. Morozov, A.E. Ayoub, M. Chatterjee, P. Rakic, and T.F. Haydar. 2006. Molecular  
764 and morphological heterogeneity of neural precursors in the mouse neocortical  
765 proliferative zones. *J Neurosci.* 26:1045-1056.

766 Gaspard, N., and P. Vanderhaeghen. 2011. From stem cells to neural networks: recent advances  
767 and perspectives for neurodevelopmental disorders. *Dev Med Child Neurol.* 53:13-17.

768 Greig, L.C., M.B. Woodworth, M.J. Galazo, H. Padmanabhan, and J.D. Macklis. 2013.  
769 Molecular logic of neocortical projection neuron specification, development and  
770 diversity. *Nat Rev Neurosci.* 14:755-769.

771 Haubensak, W., A. Attardo, W. Denk, and W.B. Huttner. 2004. Neurons arise in the basal  
772 neuroepithelium of the early mammalian telencephalon: a major site of neurogenesis.  
773 *Proc Natl Acad Sci U S A.* 101:3196-3201.

774 Haydar, T.F., E. Ang, Jr., and P. Rakic. 2003. Mitotic spindle rotation and mode of cell division  
775 in the developing telencephalon. *Proc Natl Acad Sci U S A.* 100:2890-2895.

776 Hegedus, B., B. Dasgupta, J.E. Shin, R.J. Emmett, E.K. Hart-Mahon, L. Elghazi, E. Bernal-  
777 Mizrachi, and D.H. Gutmann. 2007. Neurofibromatosis-1 regulates neuronal and glial  
778 cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-  
779 dependent mechanisms. *Cell Stem Cell.* 1:443-457.

780 Heng, Y.W., and C.G. Koh. 2010. Actin cytoskeleton dynamics and the cell division cycle. *Int*  
781 *J Biochem Cell Biol.* 42:1622-1633.

782 Hidese, S., K. Hattori, D. Sasayama, T. Miyakawa, R. Matsumura, Y. Yokota, I. Ishida, J.  
783 Matsuo, T. Noda, S. Yoshida, T. Teraishi, H. Hori, M. Ota, and H. Kunugi. 2017.  
784 Cerebrospinal fluid neural cell adhesion molecule levels and their correlation with  
785 clinical variables in patients with schizophrenia, bipolar disorder, and major depressive  
786 disorder. *Prog Neuropsychopharmacol Biol Psychiatry.* 76:12-18.

787 Hubschmann, M.V., G. Skladchikova, E. Bock, and V. Berezin. 2005. Neural cell adhesion

788 molecule function is regulated by metalloproteinase-mediated ectodomain release. *J*  
789 *Neurosci Res.* 80:826-837.

790 Jacobs, S., and L.C. Doering. 2010. Astrocytes prevent abnormal neuronal development in the  
791 fragile x mouse. *J Neurosci.* 30:4508-4514.

792 Kim, B.W., and H. Son. 2006. Neural cell adhesion molecule (NCAM) induces neuronal  
793 phenotype acquisition in dominant negative MEK1-expressing hippocampal neural  
794 progenitor cells. *Exp Mol Med.* 38:732-738.

795 Kim, J.H., J.H. Lee, J.Y. Park, C.H. Park, C.O. Yun, S.H. Lee, Y.S. Lee, and H. Son. 2005.  
796 Retrovirally transduced NCAM140 facilitates neuronal fate choice of hippocampal  
797 progenitor cells. *J Neurochem.* 94:417-424.

798 Klein, R., S. Blaschke, B. Neumaier, H. Endepols, R. Graf, M. Keuters, J. Hucklenbroich, M.  
799 Albrechtsen, S. Rees, G.R. Fink, M. Schroeter, and M.A. Rueger. 2014. The synthetic  
800 NCAM mimetic peptide FGL mobilizes neural stem cells in vitro and in vivo. *Stem Cell*  
801 *Rev.* 10:539-547.

802 Kohl, C., O. Riccio, J. Grosse, O. Zanoletti, C. Fournier, S.M. Klampfl, M.V. Schmidt, and C.  
803 Sandi. 2013. The interplay of conditional NCAM-knockout and chronic unpredictable  
804 stress leads to increased aggression in mice. *Stress.* 16:647-654.

805 Kohwi, M., and C.Q. Doe. 2013. Temporal fate specification and neural progenitor competence  
806 during development. *Nat Rev Neurosci.* 14:823-838.

807 Korshunova, I., V. Novitskaya, D. Kiryushko, N. Pedersen, K. Kolkova, E. Kropotova, M.  
808 Mosevitsky, M. Rayko, J.S. Morrow, I. Ginzburg, V. Berezin, and E. Bock. 2007. GAP-  
809 43 regulates NCAM-180-mediated neurite outgrowth. *J Neurochem.* 100:1599-1612.

810 Kunda, P., and B. Baum. 2009. The actin cytoskeleton in spindle assembly and positioning.  
811 *Trends Cell Biol.* 19:174-179.

812 Kurtz, A., A. Zimmer, F. Schnutgen, G. Bruning, F. Spener, and T. Muller. 1994. The expression

813 pattern of a novel gene encoding brain-fatty acid binding protein correlates with  
814 neuronal and glial cell development. *Development*. 120:2637-2649.

815 Lamprecht, R., C.R. Farb, S.M. Rodrigues, and J.E. LeDoux. 2006. Fear conditioning drives  
816 profilin into amygdala dendritic spines. *Nat Neurosci*. 9:481-483.

817 Li, S., I. Leshchyns'ka, Y. Chernyshova, M. Schachner, and V. Sytnyk. 2013. The neural cell  
818 adhesion molecule (NCAM) associates with and signals through p21-activated kinase 1  
819 (Pak1). *J Neurosci*. 33:790-803.

820 Luxenburg, C., H.A. Pasolli, S.E. Williams, and E. Fuchs. 2011. Developmental roles for Srf,  
821 cortical cytoskeleton and cell shape in epidermal spindle orientation. *Nat Cell Biol*.  
822 13:203-214.

823 Ma, Q.H., T. Futagawa, W.L. Yang, X.D. Jiang, L. Zeng, Y. Takeda, R.X. Xu, D. Bagnard, M.  
824 Schachner, A.J. Furley, D. Karagogeos, K. Watanabe, G.S. Dawe, and Z.C. Xiao. 2008.  
825 A TAG1-APP signalling pathway through Fe65 negatively modulates neurogenesis. *Nat*  
826 *Cell Biol*. 10:283-294.

827 Michaelsen, K., K. Murk, M. Zagrebelsky, A. Dreznjak, B.M. Jockusch, M. Rothkegel, and M.  
828 Korte. 2010. Fine-tuning of neuronal architecture requires two profilin isoforms. *Proc*  
829 *Natl Acad Sci U S A*. 107:15780-15785.

830 Miller, F.D., and A.S. Gauthier. 2007. Timing is everything: Making neurons versus glia in the  
831 developing cortex. *Neuron*. 54:357-369.

832 Miralles, F., and N. Visa. 2006. Actin in transcription and transcription regulation. *Curr Opin*  
833 *Cell Biol*. 18:261-266.

834 Molofsky, A.V., R. Krencik, E.M. Ullian, H.H. Tsai, B. Deneen, W.D. Richardson, B.A. Barres,  
835 and D.H. Rowitch. 2012. Astrocytes and disease: a neurodevelopmental perspective.  
836 *Genes Dev*. 26:891-907.

837 Paquin, A., C. Hordo, D.R. Kaplan, and F.D. Miller. 2009. Costello syndrome H-Ras alleles

838 regulate cortical development. *Dev Biol.* 330:440-451.

839 Pillai-Nair, N., A.K. Panicker, R.M. Rodriguiz, K.L. Gilmore, G.P. Demyanenko, J.Z. Huang,  
840 W.C. Wetsel, and P.F. Maness. 2005. Neural cell adhesion molecule-secreting transgenic  
841 mice display abnormalities in GABAergic interneurons and alterations in behavior. *J*  
842 *Neurosci.* 25:4659-4671.

843 Pilo-Boyl, P., A. Di Nardo, C. Mulle, M. Sassoe-Pognetto, P. Panzanelli, A. Mele, M. Kneussel,  
844 V. Costantini, E. Perlas, M. Massimi, H. Vara, M. Giustetto, and W. Witke. 2007.  
845 Profilin2 contributes to synaptic vesicle exocytosis, neuronal excitability, and novelty-  
846 seeking behavior. *EMBO J.* 26:2991-3002.

847 Politis, P.K., D. Thomaidou, and R. Matsas. 2008. Coordination of cell cycle exit and  
848 differentiation of neuronal progenitors. *Cell cycle.* 7:691-697.

849 Pollerberg, G.E., M. Schachner, and J. Davoust. 1986. Differentiation state-dependent surface  
850 mobilities of two forms of the neural cell adhesion molecule. *Nature.* 324:462-465.

851 Prodromidou, K., F. Papastefanaki, T. Sklaviadis, and R. Matsas. 2014. Functional cross-talk  
852 between the cellular prion protein and the neural cell adhesion molecule is critical for  
853 neuronal differentiation of neural stem/precursor cells. *Stem Cells.* 32:1674-1687.

854 Puchkov, D., I. Leshchyns'ka, A.G. Nikonenko, M. Schachner, and V. Sytnyk. 2011.  
855 NCAM/spectrin complex disassembly results in PSD perforation and postsynaptic  
856 endocytic zone formation. *Cereb Cortex.* 21:2217-2232.

857 Purcell, A.E., M.M. Rocco, J.A. Lenhart, K. Hyder, A.W. Zimmerman, and J. Pevsner. 2001.  
858 Assessment of neural cell adhesion molecule (NCAM) in autistic serum and  
859 postmortem brain. *J Autism Dev Disord.* 31:183-194.

860 Schluter, K., B.M. Jockusch, and M. Rothkegel. 1997. Profilins as regulators of actin dynamics.  
861 *Biochim Biophys Acta.* 1359:97-109.

862 Secher, T. 2010. Soluble NCAM. *In* Structure and Function of the Neural Cell Adhesion

863 Molecule NCAM. V. Berezin, editor. Springer, New York, USA. 227-242.

864 Seki, T., and Y. Arai. 1991. Expression of highly polysialylated NCAM in the neocortex and  
865 piriform cortex of the developing and the adult rat. *Anat Embryol (Berl)*. 184:395-401.

866 Seuntjens, E., A. Nityanandam, A. Miquelajauregui, J. Debruyne, A. Stryjewska, S. Goebbels,  
867 K.A. Nave, D. Huylebroeck, and V. Tarabykin. 2009. Sip1 regulates sequential fate  
868 decisions by feedback signaling from postmitotic neurons to progenitors. *Nat Neurosci*.  
869 12:1373-1380.

870 Shetty, A., V. Sytnyk, I. Leshchyn'ska, D. Puchkov, V. Haucke, and M. Schachner. 2013. The  
871 neural cell adhesion molecule promotes maturation of the presynaptic endocytotic  
872 machinery by switching synaptic vesicle recycling from adaptor protein 3 (AP-3)- to  
873 AP-2-dependent mechanisms. *J Neurosci*. 33:16828-16845.

874 Shin, M.H., E.G. Lee, S.H. Lee, Y.S. Lee, and H. Son. 2002. Neural cell adhesion molecule  
875 (NCAM) promotes the differentiation of hippocampal precursor cells to a neuronal  
876 lineage, especially to a glutamatergic neural cell type. *Exp Mol Med*. 34:401-410.

877 Sloan, S.A., and B.A. Barres. 2014. Mechanisms of astrocyte development and their  
878 contributions to neurodevelopmental disorders. *Curr Opin Neurobiol*. 27:75-81.

879 Soroka, V., K. Kolkova, J.S. Kastrop, K. Diederichs, J. Breed, V.V. Kiselyov, F.M. Poulsen, I.K.  
880 Larsen, W. Welte, V. Berezin, E. Bock, and C. Kasper. 2003. Structure and interactions  
881 of NCAM Ig1-2-3 suggest a novel zipper mechanism for homophilic adhesion.  
882 *Structure*. 11:1291-1301.

883 Stork, O., H. Welzl, H. Cremer, and M. Schachner. 1997. Increased intermale aggression and  
884 neuroendocrine response in mice deficient for the neural cell adhesion molecule  
885 (NCAM). *Eur J Neurosci*. 9:1117-1125.

886 Stork, O., H. Welzl, C.T. Wotjak, D. Hoyer, M. Delling, H. Cremer, and M. Schachner. 1999.  
887 Anxiety and increased 5-HT1A receptor response in NCAM null mutant mice. *J*

888 *Neurobiol.* 40:343-355.

889 Stork, O., H. Welzl, D. Wolfer, T. Schuster, N. Mantei, S. Stork, D. Hoyer, H. Lipp, K. Obata,  
890 and M. Schachner. 2000. Recovery of emotional behaviour in neural cell adhesion  
891 molecule (NCAM) null mutant mice through transgenic expression of NCAM180. *Eur*  
892 *J Neurosci.* 12:3291-3306.

893 Suetsugu, S., H. Miki, and T. Takenawa. 1999. Distinct roles of profilin in cell morphological  
894 changes: microspikes, membrane ruffles, stress fibers, and cytokinesis. *FEBS Lett.*  
895 457:470-474.

896 Sytnyk, V., I. Leshchyns'ka, A.G. Nikonenko, and M. Schachner. 2006. NCAM promotes  
897 assembly and activity-dependent remodeling of the postsynaptic signaling complex. *J*  
898 *Cell Biol.* 174:1071-1085.

899 Sytnyk, V., I. Leshchyns'ka, and M. Schachner. 2017. Neural Cell Adhesion Molecules of the  
900 Immunoglobulin Superfamily Regulate Synapse Formation, Maintenance, and  
901 Function. *Trends Neurosci.* 40:295-308.

902 Tartaglia, M., E.L. Mehler, R. Goldberg, G. Zampino, H.G. Brunner, H. Kremer, I. van der  
903 Burgt, A.H. Crosby, A. Ion, S. Jeffery, K. Kalidas, M.A. Patton, R.S. Kucherlapati, and  
904 B.D. Gelb. 2001. Mutations in PTPN11, encoding the protein tyrosine phosphatase  
905 SHP-2, cause Noonan syndrome. *Nat Genet.* 29:465-468.

906 Thakar, R.G., Q. Cheng, S. Patel, J. Chu, M. Nasir, D. Liepmann, K. Komvopoulos, and S. Li.  
907 2009. Cell-Shape Regulation of Smooth Muscle Cell Proliferation. *Biophys J.* 96:3423-  
908 3432.

909 Urosevic, J., V. Sauzeau, M.L. Soto-Montenegro, S. Reig, M. Desco, E.M. Wright, M.  
910 Canamero, F. Mulero, S. Ortega, X.R. Bustelo, and M. Barbacid. 2011. Constitutive  
911 activation of B-Raf in the mouse germ line provides a model for human cardio-facio-  
912 cutaneous syndrome. *Proc Natl Acad Sci U S A.* 108:5015-5020.

913 Vicente, A.M., F. Macciardi, M. Verga, A.S. Bassett, W.G. Honer, G. Bean, and J.L. Kennedy.  
914 1997. NCAM and schizophrenia: genetic studies. *Mol Psychiatry*. 2:65-69.

915 Wang, D.D., and A. Bordey. 2008. The astrocyte odyssey. *Prog Neurobiol*. 86:342-367.

916 Wang, W., L. Wang, J. Luo, Z.Q. Xi, X.F. Wang, G.J. Chen, and L. Chu. 2012. Role of a Neural  
917 Cell Adhesion Molecule Found in Cerebrospinal Fluid as a Potential Biomarker for  
918 Epilepsy. *Neurochem Res*. 37:819-825.

919 Witke, W. 2004. The role of profilin complexes in cell motility and other cellular processes.  
920 *Trends Cell Biol*. 14:461-469.

921 Witke, W., A.V. Podtelejnikov, A. Di Nardo, J.D. Sutherland, C.B. Gurniak, C. Dotti, and M.  
922 Mann. 1998. In mouse brain profilin I and profilin II associate with regulators of the  
923 endocytic pathway and actin assembly. *EMBO J*. 17:967-976.

924 Wood, G.K., H. Tomasiewicz, U. Rutishauser, T. Magnuson, R. Quirion, J. Rochford, and L.K.  
925 Srivastava. 1998. NCAM-180 knockout mice display increased lateral ventricle size and  
926 reduced prepulse inhibition of startle. *Neuroreport*. 9:461-466.

927 Wu, Z.Q., D. Li, Y. Huang, X.P. Chen, W. Huang, C.F. Liu, H.Q. Zhao, R.X. Xu, M. Cheng, M.  
928 Schachner, and Q.H. Ma. 2017. Caspr Controls the Temporal Specification of Neural  
929 Progenitor Cells through Notch Signaling in the Developing Mouse Cerebral Cortex.  
930 *Cereb Cortex*. 27:1369-1385.

931 Zdaniuk, G., T. Wierzba-Bobrowicz, G.M. Szpak, and T. Stepień. 2011. Astroglia disturbances  
932 during development of the central nervous system in fetuses with Down's syndrome.  
933 *Folia Neuropathol*. 49:109-114.

934 **Nonstandard abbreviations:**

935 A, alanine; C, cysteine; cKO, conditional knockout; CP, cortical plate; CSI, cell shape index;  
936 E, embryonic day; G-actin, globular actin; GFAP, glial fibrillary acidic protein; ICD,  
937 intracellular domain; IPCs, intermediate progenitor cells; IZ, intermediate zone; L, leucine;  
938 MZ, marginal zone; N, asparagine; NCAM, neural cell adhesion molecule; NPCs, neural  
939 progenitor cells; P, postnatal day; Q, glutamine; RGCs, radial glial cells; S, serine; siProfilin2,  
940 profilin2 siRNA; SVZ, subventricular zone; VZ, ventricular zone.

941 **Figure legends**

942

943 **Figure 1. NCAM is dynamically expressed in NPCs during cortical development.**

944 **A, B:** Coronal sections of mouse cortices from indicated embryonic stages were co-  
945 immunostained for NCAM and Sox2 (A) or Tuj1 (B). Scale bars: 50  $\mu$ m. **C:** Percentages of  
946 NCAM<sup>+</sup> immunoreactivity in each layer. **D:** Average immunofluorescence density of NCAM  
947 in each layer. n=9 brain slices from 3 mice. Values represent mean $\pm$ SEM. \* $P$ <0.05, \*\* $P$ <0.01;  
948 \*\*\* $P$ <0.001 (two-sided). One-way ANOVA with Bonferroni corrections (C (IZ, CP and MZ)  
949 and D (MZ)), Dunnett's T3 correction (C (VZ/SVZ)), Kruskal-Wallis test with Dunn-  
950 Bonferroni correction (D (VZ/SVZ, IZ, and CP)). VZ/SVZ, ventricular zone/subventricular  
951 zone. PP, preplate. IZ, intermediate zone. CP, cortical plate. MZ, marginal zone.

952

953 **Figure 2. NCAM deficiency transiently suppresses NPC proliferation *in vivo*.**

954 **A:** Coronal sections of control and NCAM cKO cortices were co-immunostained for BrdU and  
955 Pax6 30 min after BrdU injection. **B-D:** Numbers of Pax6<sup>+</sup> (B), BrdU<sup>+</sup> (C) cells, and  
956 percentages of Pax6<sup>+</sup>BrdU<sup>+</sup> cells in total Pax6<sup>+</sup> cell population (D). **E-J:** Coronal sections of  
957 control and NCAM cKO cortices were immunostained for Tbr2 (E), Ki67 (G) or PH3 (I) with  
958 DAPI counterstaining. Numbers of Tbr2<sup>+</sup> (F), Ki67<sup>+</sup> (H), and PH3<sup>+</sup> (J) cells in the VZ/SVZ. **K:**  
959 Coronal sections of E14 control and NCAM cKO cortices were co-immunostained for BrdU  
960 and Ki67. **L, M:** Percentages of BrdU<sup>+</sup>Ki67<sup>-</sup> cells in the total BrdU<sup>+</sup> cell population (L) and  
961 percentages of BrdU<sup>+</sup>Ki67<sup>+</sup> cells in the total Ki67<sup>+</sup> cell population (M). Scale bars: 50  $\mu$ m. n=15  
962 brain slices from 3 mice. Values represent mean $\pm$ SEM. \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ <0.001 (two-  
963 sided). Student's t test or Mann-Whitney test (B (E12), C (E12), and F (E14)).

964

965 **Figure 3. NCAM deficiency reduces numbers of cortical neurons at early, but not later**

966 **developmental stages.**

967 **A-C:** Coronal sections of control and NCAM cKO cortices were immunostained for Tbr1 (A),  
968 Ctip2 (B), and Cux1 (C) with DAPI counterstaining. Scale bars: 50  $\mu\text{m}$ . **D-F:** Numbers of Tbr1<sup>+</sup>  
969 (D), Ctip2<sup>+</sup> (E), and Cux1<sup>+</sup> (F) cells per  $2.5 \times 10^4 \mu\text{m}^2$ . n=15 brain slices from 3 mice. Values  
970 represent mean $\pm$ SEM. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  (two-sided). Student's t test or Mann-  
971 Whitney test (D(E14)).

972

973 **Figure 4. NCAM deficiency delays the generation of cortical neurons *in vivo*.**

974 **A, B:** Cortical sections of E18 control and NCAM cKO mice were co-immunostained for BrdU  
975 and Tbr1 (A) or Ctip2 (B). BrdU was injected at E11.5, E14.5 or E15.5. **C:** Cortical sections of  
976 P2 control and NCAM cKO mice were co-immunostained for BrdU and Cux1. BrdU was  
977 injected at E16.5. Scale bars: 50  $\mu\text{m}$ . **D-G:** Percentages of BrdU<sup>+</sup>Tbr1<sup>+</sup>, BrdU<sup>+</sup>Ctip2<sup>+</sup> or  
978 BrdU<sup>+</sup>Cux1<sup>+</sup> cells in total populations of Tbr1<sup>+</sup>, Ctip2<sup>+</sup>, or Cux1<sup>+</sup> cells after BrdU  
979 administration at E11.5 (D), E14.5 (E), E14.5 (F) or E16.5 (G). n=15 brain slices from 3 mice.  
980 Values represent mean $\pm$ SEM. \* $P < 0.05$ , \*\* $P < 0.01$  (two-sided). Student's t test or Mann-  
981 Whitney test (E, F (BrdU<sup>+</sup>Ctip2<sup>+</sup> cells)).

982

983 **Figure 5. NCAM deficiency results in precocious gliogenesis.**

984 **A:** Coronal sections of the VZ were immunostained for GFAP with DAPI counterstaining. **B:**  
985 Densities of GFAP<sup>+</sup> cells in the dorsolateral VZ. **C:** Total intensity of GFAP labelling per E16  
986 VZ/SVZ. **D:** Coronal sections of the dorsolateral VZ of P2 control and NCAM cKO mice were  
987 co-immunostained for BrdU and GFAP. BrdU was injected at E16.5. **E:** Numbers of  
988 BrdU<sup>+</sup>GFAP<sup>+</sup> per  $2.0 \times 10^4 \mu\text{m}^2$  in the dorsolateral VZ. **F:** Coronal cortical sections of E18 and  
989 P0 control and NCAM cKO mice were immunostained for Olig2 with DAPI counterstaining.  
990 **G:** Numbers of Olig2<sup>+</sup> cells per  $2.5 \times 10^4 \mu\text{m}^2$ . **H:** Percentages of BrdU<sup>+</sup>Olig2<sup>+</sup> cells in the total

991 Olig2<sup>+</sup> cell population. **I:** Coronal sections of the dorsal VZ of P2 control and NCAM cKO  
992 mice were co-immunostained for BrdU and Olig2. BrdU was injected at E16.5. **J:** Cortical  
993 sections of E16 control and NCAM cKO mice were immunostained for A2B5 with DAPI  
994 counterstaining. **K:** Densities of A2B5<sup>+</sup> cells. **L:** Cortical sections of E14 control and NCAM  
995 cKO mice were immunostained for BLBP<sup>+</sup> with DAPI counterstaining. **M:** Densities of BLBP<sup>+</sup>  
996 cells. Scale bars: 50 μm. n=15 brain slices from 3 mice. Values represent mean±SEM. \**P*<0.05,  
997 \*\**P*<0.01, \*\*\**P*<0.001 (two-sided). Student's t test or Mann-Whitney test (C, H).

998

999 **Figure 6. Profilin2 is a novel binding partner of NCAM.**

1000 **A:** Co-immunoprecipitation analysis of the interaction between NCAM and profilin2 using P0  
1001 mouse brain homogenates. **B:** ELISA analysis of the binding of NCAM140ICD or  
1002 NCAM180ICD to immobilized profilin2. **C-E:** ELISA analysis of the binding of biotinylated  
1003 NCAM140ICD-derived peptides (C), wildtype NCAM140 (aa745-753) peptide and its mutant  
1004 variants with <sup>749</sup>LC<sup>750</sup> mutated to <sup>749</sup>AS<sup>750</sup>, or <sup>748</sup>NL<sup>749</sup> mutated to <sup>748</sup>GA<sup>749</sup> (D), wildtype  
1005 NCAM140ICD or mutNCAM140ICD (<sup>749</sup>LC<sup>750</sup> to <sup>749</sup>AS<sup>750</sup> mutation, E), to immobilized  
1006 profilin2. n=3 biological replicates. **F:** Schematic diagram of amino acid mutations in  
1007 mutNCAM140ICD. **G, H:** Coronal sections of the VZ (G) and the cortex (H) of control mice  
1008 were co-immunostained for profilin2, NCAM and Sox2 (G) or Tuj1 (H). Scale bars: 50 μm. **I:**  
1009 Average profilin2 immunofluorescence density in each layer. **J:** Percentages of profilin2  
1010 immunoreactivity in each layer. n=9 brain slices from 3 mice. **K, L:** Western blot analysis of  
1011 levels of NCAM and profilin2 in cultured NPCs derived from E14 control and NCAM cKO  
1012 VZ/SVZ (K). The relative levels of profilin2 protein in NCAM cKO NPCs, with the profilin2  
1013 levels in control NPCs set to 100% (L), n=4 biological replicates. **M:** qPCR analysis of the  
1014 levels of profilin2 mRNA in cultured NPCs derived from E14 control and NCAM cKO brains.  
1015 Profilin2 mRNA levels in control NPCs were set to 100%, n=5 biological replicates. Values

1016 represent mean $\pm$ SEM. \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ <0.001 (two-sided). Two-way ANOVA (B-E);  
1017 One-way ANOVA with Bonferroni corrections (J (IZ, CP and MZ), Dunnett's T3 correction (J  
1018 (VZ/SVZ)); Kruskal-Wallis test with Dunn-Bonferroni corrections (I); paired t test (L, M).  
1019 VZ/SVZ, ventricular zone/subventricular zone. PP, preplate. IZ, intermediate zone. CP, cortical  
1020 plate. MZ, marginal zone.

1021

1022 **Figure 7. NCAM enhances NPC proliferation and differentiation through profilin2.**

1023 **A:** Cultured NPCs transfected with siProfilin2 or scrambled siRNA (NC) were incubated with  
1024 NCAM antibodies and BrdU. Cells were immunostained for BrdU with DAPI counterstaining.  
1025 **B, E, F:** Cultured NPCs transfected with siProfilin2 or NC were incubated with NCAM  
1026 antibodies or PBS and cultured in differentiation condition for 5 days. Cells were  
1027 immunostained for Tuj1 (B), GFAP (E) or O4 (F), and counterstained with DAPI. **C, D, G, H:**  
1028 Percentages of BrdU<sup>+</sup>DAPI<sup>+</sup> (C), Tuj1<sup>+</sup>DAPI<sup>+</sup> (D), GFAP<sup>+</sup>DAPI<sup>+</sup> (G) and O4<sup>+</sup>DAPI<sup>+</sup> (H) cells  
1029 in the total population of DAPI<sup>+</sup> cells. **I-K:** Cultured NPCs cotransfected with profilin2 shRNA  
1030 (shProfilin2) and shProfilin2-resistant plasmids (Res Profilin2), shProfilin2 or control vector  
1031 expressing GFP alone (GFP) were incubated with NCAM antibodies or PBS and allowed to  
1032 differentiate for 3 days. Cells were immunostained for Tuj1 or GFAP. Percentages of Tuj1<sup>+</sup>GFP<sup>+</sup>  
1033 (J), GFAP<sup>+</sup>GFP<sup>+</sup> cells (K) in the total population of GFP<sup>+</sup> cells. n=15 microscopic fields from  
1034 3 biological replicates. Scale bars: 50  $\mu$ m (A, F, I) or 20  $\mu$ m (B, E). Values represent  
1035 mean $\pm$ SEM. \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ <0.001 (two-sided); ns: not statistically significant.  
1036 Kruskal-Wallis test with Dunn-Bonferroni post hoc correction (C); One-way ANOVA with  
1037 Bonferroni corrections (D, G, J, K), or Dunnett's T3 correction (H).

1038

1039 **Figure 8. NCAM enhances NPC proliferation and differentiation through profilin2-**  
1040 **regulated actin dynamics.**

1041 **A:** Western blot analysis of F- and G-actin levels in cultured control and NCAM cKO NPCs.  $\gamma$ -  
1042 tubulin served as a control and was enriched in the F-actin fraction containing polymerized  
1043 tubulin. **B:** Relative levels of G- and F-actin in NCAM cKO NPCs. The levels of G- and F-actin  
1044 in control NPCs were set to 100%. n=4 biological replicates. **C:** Cultured MEFs were  
1045 cotransfected with NCAM siRNA (siNCAM) or scrambled siRNA (NC), and with lentiviruses  
1046 co-expressing GFP and wild type NCAM140 (NCAM) or mutant NCAM140 (mutNCAM).  
1047 MEFs cotransfected with NC and lentiviruses expressing GFP only served as control. Western  
1048 blot analysis of levels of NCAM, actin and tubulin. Lysis with the F-actin stabilization buffer  
1049 solubilizes and releases NCAM to the G-actin fraction. Relative levels of NCAM protein in the  
1050 G-actin fraction and the relative ratio of G- and F-actin were quantified. n=3 biological  
1051 replicates. **D:** Cultured NCAM cKO NPCs were transduced with lentiviruses co-expressing  
1052 GFP and NCAM or mutNCAM. NPCs transduced with lentiviruses expressing GFP only served  
1053 as control. NPCs were stained by fluorescent Phalloidin to visualize F-actin, and DNase I to  
1054 visualize G-actin. **E, F:** F-actin/G-actin ratios in cells are shown in D and G, respectively. n=54  
1055 cells (E), 21 cells (F) from 3 biological replicates. **G:** Cultured NCAM cKO NPCs were  
1056 transduced with plasmids co-encoding GFP, or profilin2 and GFP, stained with fluorescent  
1057 Phalloidin and DNase I. **H:** Coronal VZ sections of E12 control and NCAM cKO mice were  
1058 immunostained for actin with DAPI counterstaining. White dotted lines show examples of cell  
1059 boundaries. **I:** The CSI for dividing cells in the VZ. n=40 mitotic cells from 3 mice. **J, K:**  
1060 Cultured NCAM cKO NPCs were transduced with lentiviruses co-expressing GFP and NCAM  
1061 or mutNCAM, incubated with BrdU, and immunostained for BrdU with DAPI counterstaining  
1062 (J). Cultured NPCs differentiated for 5-7 days were immunostained for Tuj1, GFAP with DAPI  
1063 counterstaining (K). **L-N:** Percentages of BrdU<sup>+</sup>GFP<sup>+</sup> (L), Tuj1<sup>+</sup>GFP<sup>+</sup> (M) and GFAP<sup>+</sup>GFP<sup>+</sup> (N)  
1064 cells in total GFP<sup>+</sup> cell population. n=32 microscope fields from 3 biological replicates (L). n=5  
1065 biological replicates (M and N). Scale bars: 20  $\mu$ m (D, G, J, K) or 5  $\mu$ m (H). Values represent

1066 mean±SEM. \* $P<0.05$ , \*\* $P<0.01$ , \*\*\* $P<0.001$  (two-sided); ns: not statistically significant.  
1067 Paired t test (B); Mann-Whitney test (I); one-way ANOVA with Dunnett's T3 correction (C) or  
1068 Bonferroni corrections (M, N). Kruskal-Wallis test with Dunn-Bonferroni post hoc  
1069 comparisons (E, F, and L).

1070

1071 **Figure 9. The role of NCAM in regulating the temporal generation of neurons and glia in**  
1072 **the developing cortex.**

1073 **A:** NCAM expression is high in NPCs at the neurogenic period and declines at the gliogenic  
1074 period. The intracellular domain of NCAM interacts with profilin2 and promotes actin  
1075 polymerization in NPCs. NCAM-dependent actin regulation is required for rounding of NPCs  
1076 during mitosis as well as control of NPC proliferation and temporal differentiation into cortical  
1077 neurons and glia. **B:** Ablation of NCAM expression in NPCs results in reduced expression of  
1078 profilin2 and loss of its NCAM-dependent regulation, leading to decreased actin polymerization  
1079 and reduced rounding of mitotic NPCs. This slows down cell cycle progression, reduces NPC  
1080 proliferation at early stage of neural development, delays production of cortical neurons, and  
1081 leads to precocious formation of cortical glia.

1082

1083 **Supplementary Information**

1084

1085 **Supplementary figure legends**

1086

1087 **Figure S1. Expression of NCAM and profilin2 in the developing cerebral cortex.**

1088 **A-G:** Western blot analysis of NCAM and profilin2 expression in E12, E14, E16, E18, and P0  
1089 mouse cortices.  $\gamma$ -tubulin served as a control. The protein levels in E14, E16, E18, and P0 mouse  
1090 cortices were quantified relative to the protein levels in E12 mouse cortices set to 1.0. n=3 or 4  
1091 biological replicates (total NCAM and profilin2, respectively). **H:** Coronal sections of control  
1092 and NCAM cKO mouse cortices were co-immunostained for NCAM and Sox2 at E12 and E14.  
1093 Scale bars: 20  $\mu$ m. Values represent mean $\pm$ SEM. \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ <0.001 (two-sided).  
1094 One-way ANOVA with LSD corrections (C, F), with Dunnett's T3 correction (B, D, and E) or  
1095 Kruskal-Wallis test with Dunn-Bonferroni post hoc comparisons (G).

1096

1097 **Figure S2. NCAM deficiency does not lead to increased NPC apoptosis during**  
1098 **embryonic development.**

1099 **A:** Coronal sections of E12, E14 and E16 control and NCAM cKO cortices were  
1100 immunostained for activated, cleaved caspase3 and counterstained with DAPI. **B:** Numbers of  
1101 caspase3<sup>+</sup> cells in the entire hemi-telencephalon cortex. Mean $\pm$ SEM values (n=15 brain slices  
1102 from 3 mice). Mann-Whitney test did not reveal statistically significant differences between  
1103 groups. Scale bars: 50  $\mu$ m. VZ/SVZ, ventricular zone/subventricular zone.

1104

1105 **Figure S3. NCAM deficiency does not affect the distribution of neonatal cortical neurons**  
1106 **in the coronal plane.**

1107 **A:** The cortical neuron distribution was analyzed by the maximum migration distance of deep-

1108 (red arrow), or upper- (blue arrow) layer neurons from ventricular zone to cortical surface/total  
1109 cortical length (purple arrow). **B-D**: Percentages of the maximum migration distance of Tbr1<sup>+</sup>  
1110 (B), Ctip2<sup>+</sup> (C) and Cux1<sup>+</sup> (D) neurons in total cortical length. Mean±SEM values (n=15 brain  
1111 slices from 3 mice). Student's t test or Mann-Whitney test (B (E12, E14) and D (E18)).

1112

1113 **Figure S4. Profilin2 expression is downregulated specifically by profilin2 RNA**  
1114 **interference.**

1115 **A**: Western blot analysis of profilin2 levels in Neuro-2a cells transfected with either profilin2  
1116 siRNA (siProfilin2) or scrambled siRNA (NC). **B**: Levels of profilin2 in siProfilin2-transfected  
1117 cells relative to those in NC-transfected cells which were set to 1.0. **C, D**: qPCR analysis of the  
1118 levels of profilin2 (C) or profilin1 (D) mRNA in cultured NPCs transfected with either profilin2  
1119 siRNA (399, 527) or NC. The mRNA levels of profilin2/1 in NC-transfected NPCs were set to  
1120 1.0. **E, F**: Western blot analysis of profilin2 levels in Neuro-2a cells transfected with scrambled  
1121 shRNA (GFP), profilin2 shRNA (shProfilin2) only, or cotransfected with shProfilin2 and  
1122 shRNA-resistant profilin2 (Res Profilin2). The levels of profilin2 protein were quantified  
1123 relative to those in GFP-transfected cells set to 1.0. **G**: NCAM levels in brain homogenates  
1124 loaded in different quantities (26, 53 78, and 104 µg). Values represent mean±SEM. n=4  
1125 biological replicates. \**P*<0.05, \*\**P*<0.01 (two-sided); ns: not statistically significant. Paired t  
1126 test (B); one-way ANOVA with Dunnett's T3 correction (C, D) or LSD corrections (F).

1127

1128 **Figure S5. Schematic diagram showing areas chosen for quantification of cells in**  
1129 **imaging analysis.**

1130 **A**: Red rectangle indicates the 100 µm x 250 µm area of interest in the DP perpendicular to the  
1131 VZ. Blue rectangle indicates the 100 µm x 250 µm areas of interest in the DP. Purple square  
1132 indicates the 150 µm x 150 µm areas of interest in DP adjacent to VZ. CM, cortical hem, MP,

1133 medial pallium, DP, dorsal pallium, LP, lateral pallium, and LV, lateral ventricle (see materials  
1134 and methods for details). **B**: Average immunofluorescence density of profilin2 in each cortical  
1135 layer. n=9 brain slices from 3 mice. Values represent mean±SEM. \* $P < 0.05$  (two-sided).  
1136 Kruskal-Wallis test with Dunn-Bonferroni post hoc test (CP); one-way ANOVA with  
1137 Bonferroni corrections (IZ and MZ). IZ, intermediate zone; CP, cortical plate; MZ, marginal  
1138 zone.